TWI581775B - Absorbent items - Google Patents

Description

Absorbent article

The present invention relates to absorbent articles for sanitary napkins, sanitary pads, incontinence pads, incontinence pads and the like.

The absorbent article in which the skin care composition is added to the top sheet of the main body portion is a conventional technique (for example, Patent Document 1). An apertured formed film is used on the top sheet of the absorbent article. Further, in the absorbent article, a wing portion formed by extending the top sheet in the width direction is provided.

[Previous Technical Literature] [Patent Literature]

[Patent Document 1] Japanese Patent Publication No. 2003-510164

In order to package the absorbent article described in Patent Document 1 and fold the wing portion, the skin care composition applied to the top sheet of the body portion is saturated with the opening portion of the top sheet of the folded wing portion to the wing portion. shape. In this case, the joint between the top sheet of the wing portion and the back sheet is weakened by the infiltrated skin care composition, and when the absorbent article is used for a long period of time, the top sheet is peeled off from the back sheet.

The present invention has an object of providing an absorbent article which suppresses peeling of a sheet which constitutes a wing portion by a composition which is applied to a top sheet of a main body portion so as to penetrate into a wing portion.

In order to solve the above problems, the present invention adopts the following configuration.

In other words, the present invention has a longitudinal direction and a width direction, and includes a top sheet having liquid permeability provided on the skin side, a liquid impervious back sheet provided on the garment side, and a liquid provided between the top sheet and the back sheet. The main body of the retaining body and the absorbent article of the pair of wings having the top sheet and the back sheet extending from the both side edges of the body portion in the width direction, and the top sheet of the body portion on the skin side The excretory opening contact area contacting at least the user's excretory opening has a composition coating layer coated with a specific composition, the top sheet being a resin film, and the top sheet having an opening in at least the discharge port contact area, and not in the wing portion There is an opening, and the top sheet has a projection in the wing.

Others of the present invention include a top sheet having a liquid permeability provided on the skin side, a liquid-impermeable back sheet provided on the garment side, and a liquid provided between the top sheet and the back sheet. Retaining absorbent body and a pair of side sheets disposed on both sides of the top sheet An absorbent article having a pair of wing portions including a side sheet and a back sheet extending from the both side edges of the main body portion in a width direction, and the top sheet on the skin side at least contacts the user's excretion The excretory opening contact region of the mouth is provided with a composition coating layer coated with a specific composition, and the side sheet is a resin film, and the side sheet does not have an opening in the wing portion but has a projection.

According to the invention, it is possible to suppress the peeling of the sheet constituting the wing portion by the composition of the top sheet applied to the main body portion soaking into the wing portion.

1‧‧‧Absorbables

2,2A‧‧‧Top sheet

3‧‧‧ Back sheet

4,4A‧‧‧ absorber

6‧‧‧ wing

7‧‧‧Adhesive

8‧‧‧Compression groove

9‧‧‧ Sealing Department

10‧‧‧ Body Department

18A‧‧‧Side sheet

21‧‧‧1st Mountain Fold

22‧‧‧2nd mountain fold

23‧‧‧ Valley Folding

24‧‧‧ Blood modifier layer

25‧‧‧ openings

26‧‧‧1st side of the mountain fold and valley fold

100‧‧‧Nonwoven manufacturing equipment

120‧‧‧pattern roller

130‧‧‧embossing processing device

140‧‧‧Back roll for back sheet

150‧‧‧Cut

160‧‧‧Modifier coating sprayer

210‧‧‧Roll of resin film sheet

212,214,216‧‧‧Resin film sheet

220‧‧‧ recess forming roller

230‧‧‧Extended tooth roll

231‧‧‧Upper roll

232‧‧‧lower roller

233,235‧‧‧ gear teeth

234‧‧‧ Gear teeth are cut in the middle

Fig. 1 is a partially broken plan view showing an embodiment of an absorbent article of the present invention.

Fig. 2 is a schematic cross-sectional view showing a cross section taken along line A-A of Fig. 1;

[Fig. 3] Fig. 3 is a view showing an outer side surface of the outer side in the width direction of the absorbent body and a first mountain formed on the top sheet of the wing portion in the top sheet of the main body portion of the absorbent article according to the embodiment of the present invention. Figure of the fold, the second mountain fold and the valley fold.

[ Fig. 4] Fig. 4 is a view for explaining a first mountain fold portion, a second mountain fold portion, and a valley fold portion formed in the excretory opening contact region in the absorbent article according to the embodiment of the present invention.

Fig. 5 is a view for explaining an absorbent article according to an embodiment of the present invention in which a wing portion is folded for packaging.

Fig. 6 is a perspective view for explaining a package including an absorbent article according to an embodiment of the present invention.

Fig. 7 is a schematic cross-sectional view showing a cross section taken along line D-D of Fig. 5.

Fig. 8 is a view for explaining a method of manufacturing an absorbent article according to an embodiment of the present invention.

[ Fig. 9] Fig. 9 is a view for explaining a concave portion forming roller used for the production of an absorbent article according to an embodiment of the present invention.

Fig. 10 is a view for explaining a region in which a concave portion is formed by a concave portion forming roller in a sheet for a top sheet.

Fig. 11 is a view for explaining an upper roll of an extended tooth roll used for the production of an absorbent article according to an embodiment of the present invention.

Fig. 12 is a view for explaining a lower roll of an extended tooth roll used for the production of an absorbent article according to an embodiment of the present invention.

Fig. 13 is a view for explaining a sheet for a top sheet extending with an extending tooth roll.

Fig. 14 is a plan view showing a modification of an embodiment of the absorbent article of the present invention.

Fig. 15 is an electron micrograph of the skin contact surface of the top sheet in the sanitary napkin of the top sheet containing the three C2L oil fatty acid glycerides.

Fig. 16 is a photomicrograph of menstrual blood with or without a blood modifying agent.

Fig. 17 is a view for explaining a method of measuring surface tension.

[Best form of implementing the invention]

Hereinafter, the present invention will be described with reference to the drawings, but the present invention is not limited by the description.

Fig. 1 is a partially broken plan view of an absorbent article according to an embodiment of the present invention, and Fig. 2 is a schematic cross-sectional view taken along line A-A of Fig. 1. The absorbent article 1 includes a liquid-permeable top sheet 2 provided on the skin side (skin contact side), a liquid-impermeable back sheet 3 and a top sheet 2 and a back provided on the garment side (non-skin contact side). The main body portion 10 of the liquid-retaining absorbent body 4 provided between the sheets 3 and the pair of wing portions 6 including the top sheet 2 and the back sheet 3 extending in the width direction from both side edges of the main body portion 10. Reference numeral 61 is the root of the wing portion 6 (the boundary between the body portion 10 and the wing portion 6). For example, in the longitudinal direction of both sides of the wing portion 6, a straight line connecting the two points of the wide and rapid increase of the absorbent article 1 can be regarded as the root portion 61 of the wing portion 6. The opposite side of the face of the dressing side of the wing portion 6 is constituted by the top sheet 2. Adhesive portions 7 are provided on the garment-side surfaces of the main body portion 10 and the wing portion 6, respectively. Moreover, in FIG. 1, the width direction of the absorbent article 1 is the X direction, and the longitudinal direction is the Y direction. Further, the plane direction of the absorbent article 1 is the XY direction.

The shape of the main body portion 10 is a shape suitable for a female body and a panty shape such as a rectangular shape, an elliptical shape, or an hourglass type, and is not particularly limited. In the outer shape of the main body portion 10, the extension in the longitudinal direction is preferably 100 to 500 mm, more preferably 150 to 350 mm. Further, in the outer shape of the main body portion 10, the extension in the width direction is preferably 30 to 200 mm, more preferably 40 to 180mm.

The top sheet 2 moves the body fluid such as urine or menstrual blood discharged from the user to the absorber 4 in the main body portion 10. Further, in the main body portion 10, at least a portion of the top sheet 2 has liquid permeability, and has a plurality of openings for allowing body fluid to permeate. On the other hand, in the wing portion 6, the top sheet 2 is adapted to be used by the user to bend the wing portion 6, and the wing portion 6 is provided with the back sheet 3, which will be described later, even if it is attached to the undergarment, and does not give the user an appropriate degree of discomfort. rigidity.

The top sheet 2 is preferably made of a resin film. As the resin film used for the top sheet 2, a copolymer of an olefin and another monomer such as acrylate or vinyl acetate, polyolefin, polyester, polypropylene, polyethylene, polyethylene terephthalate, and poly Made from guanamine, cellulose acetate, etc. From the viewpoint of high flexibility and little irritation to the skin, the resin film used as the top sheet 2 is preferably a copolymer of an olefin and another monomer, or a polyolefin.

The basis weight of the top sheet 2 is preferably 1 g/m ² or more and 40 g/m ² or less, more preferably 10 g/m ² or more and 35 g/m ² or less. Moreover, the thickness of the resin film constituting the top sheet 2 is preferably 0.01 mm or more and 0.4 mm or less, more preferably 0.1 mm or more and 0.35 mm or less. When the thickness of the resin film constituting the top sheet 2 is less than 0.01 mm, the concealability of the top sheet 2 described later becomes too small, and when the thickness of the resin film constituting the top sheet 2 exceeds 0.4 mm, the top sheet 2 is provided. The rigidity becomes high, and the stimulation of the top sheet 2 against the user's skin becomes too strong. Since the top sheet 2 has the first mountain fold portion, the second mountain fold portion, and the valley fold portion to be described later, the apparent thickness of the top sheet 2 is larger than the thickness of the resin film constituting the top sheet 2. The apparent thickness of the top sheet 2 is preferably 0.01 mm or more and 1 mm or less, more preferably 0.1 mm or more and 0.5 mm or less.

The top sheet 2 has concealability in order to prevent the body fluid absorbed by the absorber 4 from being invisible from the outside. The concealability of the top sheet 2 is produced by mixing a filler such as titanium oxide in a resin. When the filler is titanium oxide, the content of the titanium oxide is preferably 1% or more and 50% or less, more preferably 3% or more and 15% or less, based on the weight of the resin film. When the content of the titanium oxide is less than 1% by weight of the resin film, the effect of the body fluid absorbed by the absorber 4 in the concealed top sheet 2 is too small. When the content of the titanium oxide exceeds 50% by weight based on the weight of the resin film, it may be difficult to form a sheet of a resin containing titanium oxide.

The top sheet 2 has a first mountain fold portion 21 and a valley fold portion that extend in the longitudinal direction and are alternately arranged in the width direction, and a second mountain fold portion 22 that extends in a direction intersecting the first mountain fold portion 21 . The top sheet 2 of the region 12 of the absorber 4 is provided in the main body portion 10, and an opening portion to be described later is formed. Further, in the excretory port contact region 16 in the region 12 in which the absorber 4 is provided, a blood modifying agent layer to be described later is provided on the surface of the top sheet 2. Here, the excretory opening contact region 16 means that the length in the longitudinal direction centering on the position of the excretory opening contacting the user's body fluid is preferably 50 to 200 mm, more preferably 70 to 150 mm, and the length in the width direction is preferably 10 An area of the absorbent article 1 of ~80 mm, more preferably 20 to 50 mm. In order to package the absorbent article 1, the outer edge 62 of the pair of wings 6 in the width direction The pair of wings 6 are folded inwardly in the widthwise direction, and most or all of the drain contact area 16 is shielded by the folded wings 6 (see Figs. 5 and 7 for reference).

The first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion 23 provided in the top sheet 2 will be described in detail with reference to Figs. 3 and 4 . 3 is a view showing a region 14 on the outer side of the side faces 41 in the width direction of the absorbent body 4 of the main body portion 10 and a first mountain fold formed on the top sheet 2 of the wing portion 6 (FIG. 1 as a reference). A view of the portion 21, the second mountain fold portion 22, and the valley fold portion 23.

As shown in Fig. 3, in the region 14 and the wing portion 6 on the outer side of the both side faces 41 in the width direction of the absorbent body 4, the top sheet 2 is extended in the longitudinal direction (Y direction) and alternately arranged in the width direction (X direction). The first mountain fold portion 21 and the valley fold portion 23. The shape of the cross section of the first mountain fold portion 21 and the valley fold portion 23 is, for example, a substantially U-shape. In the U-shaped shape, in addition to the U-shape, a shape in which a corner is smoothly formed, a straight line is curved, or the like is applied to form a U-shape. For example, in a slightly U shape, a V shape, an M shape, a trapezoidal shape, and an Ω shape are also included.

It is preferable that the second mountain fold portion 22 extends in the intersecting direction of the first mountain fold portion 21 that extends in the longitudinal direction (Y direction). For example, the angle between the direction in which the first mountain fold portion 21 extends and the direction in which the second mountain fold portion 22 extends is preferably 10° or more and 170° or less. The shape of the cross section of the second mountain fold portion 22 when the second mountain fold portion 22 is cut in the vertical direction with respect to the direction in which the second mountain fold portion 22 extends is, for example, a substantially U-shaped shape. Further, although the second mountain fold portion 22 may not be provided on the top sheet 2, since the second mountain is formed In the folded portion 22, the first mountain fold portion 21 is less likely to collapse, and it is preferable to provide the second mountain fold portion 22 to the top sheet 2.

The number of the first mountain fold portions 21 per 1 cm in the width direction is preferably 3 or more, and more preferably 5 or more. When the number of the first mountain fold portions 21 per 1 cm in the width direction is 2 or less, the bottom portion of the valley portion 23 in the wing portion 6 contacts the drain opening contact region 16 and the blood modifying agent layer will be described later.

The length of the second mountain fold portion 22 in the longitudinal direction (Y direction) is preferably 0.3 mm or more and 5 mm or less, more preferably 0.5 mm or more and 3 mm or less. When the length ratio of the second mountain fold portion 22 in the longitudinal direction (Y direction) is 0.3 mm, there is a case where the first mountain fold portion 21 is not easily disintegrated. Further, when the length of the second mountain fold portion 22 in the longitudinal direction (Y direction) is larger than 5 mm, the contact area between the top sheet 2 and the excretion port contact region 16 in the wing portion 6 which is described later is not changed. Small situation.

In the wing portion 5, the top sheet 2 does not include an opening portion to be described later.

4 is a view showing the first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion 23 formed in the drain opening contact region 16 in the top sheet 2 of the absorbent article 1 according to the embodiment of the present invention. Figure. As shown in Fig. 4, the top sheet 2 of the excretory opening contact region 16 is the same as the outer sheet region 14 of the side surface 41 of the absorbent body 4 in the width direction of the main body portion 10 and the top sheet 2 of the wing portion 5, and includes the first mountain. The folded portion 21, the second mountain fold portion 22, and the valley fold portion 23. However, the first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion 23 of the top sheet 2 of the excretory opening contact region 16 further include a blood modifying agent layer 24 to be described later on the skin side surface. Also, the drain contact area The first mountain fold portion 21 and the valley fold portion 23 of the top sheet 2 of 16 further include an opening portion 25 on the side surface 26.

The first mountain fold portion 21 and the valley fold portion 23 of the top sheet 2 of the drain opening contact region 16 have a plurality of openings 25 arranged in the longitudinal direction (Y direction) on both side faces 26 thereof. The body fluid of the user discharged from the top sheet 2 of the excretory opening contact region 16 is moved to the absorber 4 through the opening portion 25. Further, the body liquid of the user discharged from the top sheet 2 is rapidly gathered toward the bottom of the valley portion 23 by the substantially U-shape in the width direction (X direction) formed by the valley fold portion 23. Since the opening portion 25 is provided on the side surface 26 of the first mountain fold portion 21 and the valley fold portion 23, the body fluid flowing to the bottom of the valley fold portion 23 passes through the first mountain fold portion 21 and the valley before reaching the bottom of the valley fold portion 23. The opening 25 provided in the side surface 26 of the folded portion 23 flows to the absorber 4. Further, the body fluid of the retention valley portion 23 also flows through the opening portion 25 provided in the side surface 26 of the first mountain fold portion 21 and the valley fold portion 23 to the absorber 4. Therefore, the body fluid of the user is quickly absorbed by the absorber 4 by the opening portion 25 provided in the side surface 26 of the first mountain fold portion 21 and the valley fold portion 23. Moreover, the amount of the body fluid remaining in the top sheet 2 can be reduced by the opening portion 25 provided in the side surface 26 of the first mountain fold portion 21 and the valley fold portion 23.

A blood modifying agent is applied to the surface of the skin side of the top sheet 2 of the excretory opening contact area 16. A blood modifying agent layer 24 is provided on the surface of the top sheet 2 on the skin contact side. The blood modifying agent layer 24 is folded so that the pair of wing portions 6 are folded inward in the width direction so that the edges 62 on the outer side in the width direction of the pair of wing portions 6 are in contact with each other, and are shielded by the folded wing portions 6. The range is better. Thereby, when the absorbent article 1 is packaged, the folded wing portion 6 is The blood modifying agent layer 24 is protected. By the blood modifying agent layer 24, it is possible to suppress the body fluid of the user, in particular, a body fluid having a high viscosity (for example, menstrual blood having a high viscosity) remaining on the surface of the top sheet 2. Further, if the blood modifying agent layer 24 is provided in at least the drain opening contact region 16 of the top sheet 2, the blood modifying agent layer 24 may or may not be provided in a region other than the drain opening contact region 16. This blood modifying agent layer 24 will be described in detail later.

The contact area between the skin of the user and the top sheet 2 is reduced by the first mountain fold portion 21 provided in the top sheet 2 of the excretory opening contact region 16, and the skin contact of the top sheet 2 is good. Further, only the first mountain fold portion and the valley fold portion can be formed on the top sheet 2 of the drain opening contact region 16, and the second mountain fold portion can be formed. Also in this case, the contact area between the user's skin and the top sheet 2 is small, and the skin contact of the top sheet 2 is good. However, since the first mountain fold portion is not easily broken by the provision of the second mountain fold portion, the first mountain fold portion, the second mountain fold portion, and the valley fold portion are provided in the top sheet 2 of the drain opening contact region 16. It is better.

Similarly to the drain port contact region 16 in the region 12 of the main body portion 10 in which the absorber 4 is provided, the first sheet portion 21 in which the opening portion is formed on the side surface is provided in the top sheet 2, and The valley fold portion 23 and the second mountain fold portion 22. However, in the region 12 of the main body portion 10 in which the absorbent body 4 is provided, in the region other than the excretory opening contact region 16, the blood modifying agent layer 24 is not provided on the surface of the top sheet 2.

Further, in the region 12 of the main body portion 10 in which the absorbent body 4 is provided, the blood modifying agent layer 24 may be provided on the surface of a part or all of the top sheet 2 of the region other than the excretory opening contact region 16. By this, The bodily fluid of the user who has flowed out of the excretory opening contact region 16 is left in a region other than the excretory opening contact region 16 in the region 12 in which the absorber 4 is provided.

The contact area between the skin of the user and the top sheet 2 is reduced by the first mountain fold portion 21 provided in the region other than the excretory opening contact region 16 in the region 12 of the main body portion 10 in which the absorber 4 is provided. Therefore, the skin contact of the top sheet 2 becomes good. Further, in the region 12 of the main body portion 10 in which the absorber 4 is provided, the top sheet 2 of the region other than the drain contact region 16 can form only the first mountain fold portion and the valley fold portion 23 without forming the second mountain fold portion. Also in this case, since the contact area between the user's skin and the top sheet 2 is small, the skin contact of the top sheet 2 is good. However, since the first mountain fold portion is not easily broken by the provision of the second mountain fold portion, the top sheet 2 of the region other than the drain port contact region 16 in the region 12 of the main body portion 10 in which the absorber 4 is provided It is preferable to provide the first mountain fold portion, the second mountain fold portion, and the valley fold portion 23.

At least the discharge port contact region 16 of the top sheet 2 is provided with the opening portion 25, and a part or all of the region other than the drain port contact region 16 in the region 12 in which the absorber 4 is provided may not be provided with the opening portion 25. Since the body fluid discharged from the user does not flow out of the drain port contact region 16 on the surface of the top sheet 2, the region other than the drain port contact region 16 does not need to form the opening portion 25. Further, an opening portion 25 may be provided in a portion of the outer region 14 of the outer edge 41 of the absorbent body 4 of the top sheet 2 of the main body portion 10. Thereby, since the body liquid flowing out from the region 12 of the main body portion 10 where the absorber 4 is provided is absorbed on the surface of the top sheet 2 The opening provided in the region 14 on the outer side of the both edges 41 in the width direction of the body 4 is absorbed by the absorber 4, and it is possible to further prevent the body fluid discharged from the user from leaking outward from the edge of the absorbent article 1.

The back sheet 3 shown in Figs. 1 and 2 prevents the body fluid absorbed by the absorbent body 4 from leaking to the outside. In the back sheet 3, a material that does not penetrate body fluid is used. For example, the back sheet 3 is made of a hydrophobic non-woven fabric, a water-impermeable plastic film such as polyethylene or polypropylene, or a laminated sheet of a non-woven fabric and a water-impermeable plastic film. Further, as the back sheet 3, a spunbond, melt-blown/spun-spun (SMS) fiber nonwoven fabric in which a melt-resistant nonwoven fabric having high water resistance is held by a spunbonded nonwoven fabric having high strength can be used. By using the air permeable material that does not pass the body fluid as the back sheet 3, the sultry heat during use can be reduced. The back sheet 3 is bonded to the bottom of the valley portion 23 of the top sheet 2 by using an adhesive such as a hot melt adhesive.

The absorbent body 4 absorbs body fluid and remains. The absorber 4 is preferably bulky, has a shape that is not easily broken, and is less chemically irritating. For example, as the absorber 4, a composite absorbent composed of a fluffy pulp or an airlaid nonwoven fabric and a superabsorbent polymer (SAP) is used. The composite absorbent body can also be coated with a liquid permeable material such as a woven fabric.

Further, artificial cellulose fibers such as chemical pulp, cellulose fibers, rayon, and acetate may be used instead of the raised pulp of the composite absorbent. The basis weight of the absorbent fibers such as pulp in the composite absorbent body is preferably 100 g/m ² or more and 800 g/m ² or less, and the mass ratio of the superabsorbent polymer in the composite absorbent body is based on absorbent fibers. 100%, preferably 10% or more and 65% or less. The basis weight of the liquid-permeable material such as the woven fabric covering the composite absorbent body is preferably 12 g/m ² or more and 30 g/m ² or less.

As the air-laid nonwoven fabric of the composite absorbent body, for example, a nonwoven fabric which thermally fuses pulp and synthetic fibers or a nonwoven fabric which fixes pulp and synthetic fibers with an adhesive can be used.

The superabsorbent polymer of the above composite absorbent has a three-dimensional network structure in which a water-soluble polymer is moderately crosslinked. The absorbent polymer absorbs 30 to 60 times of water relative to the volume of the absorbent polymer before absorption of water. However, the absorbent polymer is essentially water insoluble. Further, even if the absorbent polymer is applied with a slight pressure, the absorbed water does not leave the water. As the absorbent polymer, for example, a starch-based or acrylic-based particulate or fibrous polymer is used.

The shape and structure of the absorber 4 may be changed as necessary, but the total absorption amount of the absorber 4 must correspond to the design insertion amount of the absorbent article 1 and the intended use. Further, the size of the absorbent body 4, the absorbing ability, and the like are changed depending on the application.

The absorbent body 4 is followed by the top sheet 2 using a hot melt adhesive. Thereby, the top sheet 2 can be suppressed from being peeled off by the absorber 4.

As described above, the wing portion 6 is provided in the absorbent article 1 in order to securely fix the absorbent article 1 to the undergarment. After the wing portion 6 is bent on the outer side of the undergarment, the adhesive portion 7 is adhered to the pant region of the underwear through the adhesive portion 7, so that the absorbent article 1 can be stably fixed to the undergarment. Further, the body portion 10 is also provided with an adhesive portion 7 for preventing the body portion 10 from sliding in the pants region of the undergarment.

The adhesive portion 7 of the absorbent article 1 shown in Fig. 2 will absorb The sexual item 1 is fixed to the pant area of the underwear. As the adhesive for forming the adhesive portion 7, it is preferable to use, for example, any of a styrene-based polymer, an adhesion-imparting agent, and a plasticizer. Examples of the styrene-based polymer include a styrene-ethylene-butylene-styrene block copolymer, a styrene-butene polymer, a styrene-butene-styrene block copolymer, and benzene. An ethylene-isobutylene-styrene copolymer or the like may be used, but one or a mixture of two or more of these may be used. Among them, a styrene-ethylene-butylene-styrene block copolymer is preferred from the viewpoint of good thermal stability.

In addition, as the adhesion-imparting agent and the plasticizer, it is preferable to use a solid at room temperature, and examples of the adhesion-imparting agent include a C5-based petroleum resin, a C9-based petroleum resin, a dicyclopentadiene-based petroleum resin, and a rosin-based petroleum resin. The polydecene resin, the terpene phenol resin, and the like, and the plasticizer may, for example, be a monomer plasticizer such as tricresyl phosphate, dibutyl phthalate or dioctyl phthalate. Vinyl polymer or polyester polymer plasticizer.

As shown in Fig. 1 and Fig. 2, the top sheet 2 and the absorbent body 4 have compression grooves 8 formed from the top sheet 2 to the inside of the absorbent body 4 which are formed by compression in the thickness direction by embossing. The compression groove 8 suppresses the body fluid discharged from the central portion of the absorbent article 1 (portion that contacts the user's body fluid discharge port) from diffusing in the width direction (X direction). Moreover, the peeling of the top sheet 2 from the absorber 4 can be suppressed. The compression groove 8 surrounds the central portion of the absorbent article 1 and has a continuous substantially annular shape. Further, the compression groove 8 surrounding the central portion of the absorbent article 1 can be partially interrupted. That is, the compression groove 8 may also have a discontinuous, slightly annular shape.

Moreover, the top sheet 2 and the back sheet 3 are compression-bonded by heat embossing, and the sealing portion 9 is formed at the edge portion on both sides in the longitudinal direction of the main body portion 10 and the outer edge portion of the wing portion 6 in the width direction. Thereby, the top sheet 2 becomes undetachable by the back sheet 3.

Next, the above-described blood modifying agent layer 24 will be described in detail. The blood modifying agent of the blood modifying agent layer 24 has an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C or less, and a water solubility of about 0.00 to about 0.05 g for 100 g of water at 25 ° C.

IOB (Inorganic Organic Balance) is an index indicating the balance between hydrophilicity and lipophilicity, and in the present specification, the value calculated by the formula: IOB = inorganic value / organic value.

The inorganic value and the organic value are based on the organic concept map described in Fujita Mu's "Predicting and Organic Concepts of Organic Compounds" Chemical Region Vol. 11, No. 10 (1957) p. 719-725). The organic value and inorganic value of the main base of Fujita are as shown in Table 1 below.

For example, in the case of an ester of tetradecanoic acid having a carbon number of 14 and a dodecyl alcohol having a carbon number of 12, the organic value is 520 (CH ₂ , 20 × 26), and the inorganic value is 60 (-COOR, 60 ×). 1), so IOB=0.12.

The above blood modifying agent has an IOB of from about 0.00 to about 0.60, preferably from about 0.00 to about 0.50, more preferably from about 0.00 to about 0.40, and still more preferably from about 0 to about 0.30. Because of the lower IOB, the organicity is high, and the affinity with blood cells is high.

In the present specification, the "melting point" indicates the peak top temperature of the endothermic peak when the solid state is changed to a liquid state at a temperature increase rate of 10 ° C / min in the differential scanning calorimeter. The melting point can be measured by, for example, a DSC-60 DSC measuring apparatus manufactured by Shimadzu Corporation.

The above blood modifying agent, if it has a melting point of about 45 ° C or less, may be liquid or solid at room temperature, that is, the melting point may be above about 25 ° C or less than about 25 ° C, and for example, may have about -5 ° C, The melting point of about -20 ° C. The melting point of the above blood modifying agent is about 45 ° C or less, as will be described later.

Although the above-mentioned blood modifying agent has no lower limit of the melting point, it is preferred that the blood pressure is low. The vapor pressure of the above blood modifying agent is preferably from about 0.00 to about 0.01 Pa at 1 atm and 25 ° C, more preferably from about 0.000 to about 0.001 Pa, and still more preferably from about 0.0000 to about 0.0001 Pa. When the absorbent article of the present invention is used in contact with a human body, the vapor pressure is preferably from about 0.00 to about 0.01 Pa at 1 atm and 40 ° C, more preferably from about 0.000 to about 0.001 Pa, and more preferably from about 0.0000 to about 0.0001 Pa. good. When the vapor pressure is high, there is a problem that gasification during storage, a decrease in the amount of the blood modifying agent, and an odor during use are caused.

Further, the melting point of the blood modifying agent can be appropriately selected depending on the weather, the length of time of use, and the like. It is considered that, for example, in a region where the average temperature is below about 10 ° C, the blood modifying agent can be stabilized even after being cooled by the ambient temperature by using a blood modifying agent having a melting point of about 10 ° C or lower. The blood is modified. Further, when the absorbent article is used for a long period of time, the melting point of the blood modifying agent is preferably in the range of 45 ° C or lower. The blood modifying agent does not easily move even when it is used for a long period of time due to the influence of the sweat and the friction during use.

0.00 to 0.05 g of water solubility is 25 ° C, 0.05 g of sample is added to 100 g of deionized water, and allowed to stand for 24 hours. After 24 hours, gently stir as necessary, and then visually evaluate the dissolution of the sample by No to determine. Further, in the present specification, the "solubility" of the water solubility includes a case where the sample is completely dissolved in deionized water to form a homogeneous mixture, and the sample is completely emulsified. Also, "completely" means deionized water There is no briquette in the sample.

In this technical area, the surface of the top sheet is coated with a surfactant for the purpose of changing the surface tension of blood or the like to rapidly absorb blood. However, since the surfactant generally has high water solubility, the top sheet of the coated surfactant has a good affinity with hydrophilic components (plasma, etc.) in the blood, and even has a tendency to leave blood in the top sheet. The blood modifying agent is considered to have a low water solubility, and unlike the conventional surfactant, the blood is not allowed to remain on the top sheet, and can be quickly moved to the absorber.

In the present specification, the solubility in 100 g of water at 25 ° C is referred to as "water solubility".

In the present specification, the "weight average molecular weight" is a compound containing a polydisperse system (for example, a compound produced by sequential polymerization, an ester of a plurality of fatty acids and a plurality of aliphatic monohydric alcohols), and a single compound (for example, a fatty acid and 1 the concept of aliphatic monohydric alcohol esters generated), the number N _i refers to molecules with a molecular weight of M _i (i = 1, or i = 1,2‧‧‧) system consisting of the following formula: M _w = Σ N _i M _i ² / Σ N _i M _i obtained M _w .

In the present specification, the weight average molecular weight means a value in terms of polystyrene obtained by colloidal permeation chromatography (GPC). The measurement conditions of GPC are as follows, for example.

Model: (share) Hitachi High-Technologies high-speed liquid chromatography Lachrom Elite

Pipe column: SHODEX KF-801, KF-803 made by Showa Denko Electric Co., Ltd. And KF-804

Dissolution: THF

Flow rate: 1.0mL/min

Injection volume: 100μL

Detection: RI (differential refractometer)

Moreover, the weight average molecular weight described in the examples of the present specification is measured under the above conditions.

The above blood modifying agent is preferably a CC single bond of the following (i) to (iii), (i) hydrocarbon, (ii) having (ii-1) a hydrocarbon moiety, and (ii-2) the above hydrocarbon moiety. An intervening compound of one or more of the same or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-), and (iii) having a hydrocarbon moiety of (iii-1), (iii-2) one or a plurality of identical or different groups selected from the group consisting of a carbonyl group (-CO-) and an oxy group (-O-) inserted between the CC single bonds of the above hydrocarbon moiety, and (iii- 3) a compound in which one or a plurality of the same or different groups selected from the group consisting of a carboxyl group (-COOH) and a hydroxyl group (-OH) of a hydrogen atom of the above hydrocarbon moiety, and any combination thereof are grouped Elected.

In the present specification, the "hydrocarbon" is a compound composed of carbon and hydrogen, and the chain hydrocarbon may, for example, be a paraffinic hydrocarbon (also referred to as an alkane having no double bond or triple bond) or an olefin hydrocarbon (also referred to as a double). Alkene of a bond, an acetylene hydrocarbon (also referred to as an alkyne having one triple bond), and a bonded hydrocarbon selected from the group consisting of two or more double bonds and triple bonds, and a cyclic hydrocarbon can be exemplified. Aromatic Hydrocarbon, alicyclic hydrocarbon.

The above hydrocarbons are preferably a chain hydrocarbon or an alicyclic hydrocarbon, more preferably a chain hydrocarbon, a paraffinic hydrocarbon, an olefin hydrocarbon, and a hydrocarbon having two or more double bonds (excluding a triple bond) and more preferably a paraffin wax. The hydrocarbons are the best. The chain hydrocarbons include linear hydrocarbons and branched chain hydrocarbons.

In the compounds of the above (ii) and (iii), when two or more oxy groups (-O-) are inserted, each of the oxy groups (-O-) is not adjacent. Therefore, among the compounds of the above (ii) and (iii), a compound having a continuous oxy group (so-called peroxide) is not contained.

Further, in the compound of the above (iii), the compound substituted with at least one hydrogen atom of the hydrocarbon moiety by the carboxyl group (-COOH) is substituted with at least one hydrogen atom of the hydrocarbon moiety by a hydroxyl group (-OH). Compounds are preferred. As shown in Table 1, since the carboxyl group is bonded to the metal in the menstrual blood, and the inorganic value is greatly increased from 150 to 400 or more, the blood modifying agent having a carboxyl group has a value of IOB of more than about 0.60 when used. The possibility of a decrease in blood cell affinity.

More preferably, the above blood modifying agent is composed of (i') to (iii'), (i') hydrocarbon, (ii') having (ii'-1) hydrocarbon moiety, and (ii'-2) The CC bond between the hydrocarbon moiety is interposed by a carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO-), and an ether bond (-O-). One or more of the same or different bonded compounds selected, and (iii') a carbonyl bond (-CO-) or an ester bond (-COO-) having a (iii'-1) hydrocarbon moiety and a CC single bond interposed between (iii'-2) and the above hydrocarbon moiety One or a plurality of identical or different bonds selected from the group consisting of carbonate linkages (-OCOO-) and ether linkages (-O-), and (iii'-3) hydrogen substituted for the above hydrocarbon moiety The atom is selected from the group consisting of one or more of the same or different groups selected from the group consisting of a carboxyl group (-COOH) and a hydroxyl group (-OH), and any combination thereof.

In the above compounds (ii') and (iii'), when two or more identical or different linkages are inserted, that is, two or more carbonyl linkages (-CO-) and esters are inserted. Where the bond (-COO-), carbonate bond (-OCOO-), and ether bond (-O-) are the same or different bonds, the bonds are not adjacent, and there is at least a bond between the bonds. 1 carbon atom.

More preferably, the above-mentioned blood modifying agent may have a carbonyl bond (-CO-) of about 1.8 or less, an ester bond (-COO-) of 2 or less, and a carbonate bond per 10 carbon atoms in the hydrocarbon moiety. The compound (-OCOO-) is about 1.5 or less, the ether bond (-O-) is about 6 or less, the carboxyl group (-COOH) is about 0.8 or less, and/or the hydroxyl group (-OH) is about 1.2 or less.

More preferably, the blood modifying agent of the present invention has a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the chain hydrocarbon moiety described below by (A) to (F) and (A) (A1). And (A) a compound having a chain hydrocarbon moiety and a compound which substitutes one carboxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety, (B) (B1) having a chain hydrocarbon moiety and a hydrogen replacing the above chain hydrocarbon moiety; a compound having 2 to 4 hydroxyl groups of an atom and (B2) an ether having a chain hydrocarbon moiety and a hydroxyl group substituted for a hydrogen atom of the chain hydrocarbon moiety; (C) (C1) containing a chain hydrocarbon moiety and a substitution a carboxylic acid, a hydroxy acid, an alkoxy acid or a pendant oxyacid having 2 to 4 carboxyl groups of a hydrogen atom of the above-mentioned chain hydrocarbon moiety and (C2) having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety An ester of a hydroxyl group compound, (D) having a chain hydrocarbon moiety, an ether bond (-O-), a carbonyl bond (-CO-), an ester bond interposed between a CC single bond of the above chain hydrocarbon moiety ( -COO-), and a compound selected from the group consisting of carbonate linkages (-OCOO-), (E) polyoxy C ₂ -C ₆ alkanediol, or an alkyl ester or alkyl group thereof Ether, and (F) chain hydrocarbons, and In any combination of the selected groups.

Hereinafter, the blood modifying agents of (A) to (F) will be described in detail.

[(A) (A1) A compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (A2) having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety; Ester of a carboxy compound]

(A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (A2) having a chain hydrocarbon moiety An ester of a compound which is substituted with one carboxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter, also referred to as "compound (A)") may have a hydroxyl group which is not fully formed by having the above-mentioned IOB, melting point and water solubility. Esterification.

(A1) A compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the chain hydrocarbon moiety (hereinafter also referred to as "compound (A1)"), for example, a chain hydrocarbon tetraol For example, alkanol tetraols such as pentaerythritol, chain hydrocarbon triols such as alkane triols such as glycerol, and chain hydrocarbon diols such as alkane diols such as diols.

(A2) A compound having a chain hydrocarbon moiety and one carboxyl group which replaces the hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter also referred to as "compound (A2)"), for example, one hydrogen atom on a hydrocarbon A compound substituted with one carboxy group (-COOH), such as a fatty acid.

The compound (A) may, for example, be an ester of (a ₁ ) chain hydrocarbon tetraol with at least one fatty acid, (a ₂ ) a chain hydrocarbon triol with at least one fatty acid ester, and (a ₃ ) a chain hydrocarbon. An ester of a diol with at least one fatty acid.

[(a ₁ ) an ester of a chain hydrocarbon tetraol with at least one fatty acid]

The ester of the above chain hydrocarbon tetraol and at least one fatty acid can be exemplified by the following formula (1): a tetraester of pentaerythritol and a fatty acid, the following formula (2): a pentaerythritol and a fatty acid triester, the following formula (3): Diester of pentaerythritol and fatty acid, the following formula (4): a monoester of pentaerythritol and a fatty acid. (wherein, R ¹ to R ⁴ are each a chain hydrocarbon)

The fatty acid (R ¹ COOH, R ² COOH, R ³ COOH, and R ⁴ COOH) constituting the ester of pentaerythritol and a fatty acid is not particularly limited as long as the ester of pentaerythritol and a fatty acid satisfies the above requirements of IOB, melting point, and water solubility. For example, a saturated fatty acid such as a C ₂ - C ₃₀ saturated fatty acid such as acetic acid (C ₂ ) _, (C ₂ represents a carbon number, and a carbon number equivalent to R ¹ C, R ² C, R ³ C or R ⁴ C, the same below ), propane acid (C ₃ ), butanoic acid (C ₄ ) and isomers thereof, such as 2-methylpropanic acid (C ₄ ), pentanoic acid (C ₅ ) and isomers thereof, for example 2- Methyl butanoic acid (C ₅ ), 2,2-dimethylpropane acid (C ₅ ), hexane acid (C ₆ ), heptanoic acid (C ₇ ), octanoic acid (C ₈ ) and the like a structure such as 2-ethylhexane acid (C ₈ ), decanoic acid (C ₉ ), decanoic acid (C ₁₀ ), dodecanoic acid (C ₁₂ ), myristic acid (C ₁₄ ), Hexadecanic acid (C ₁₆ ), heptadecanoic acid (C ₁₇ ), octadecanoic acid (C ₁₈ ), eicosanoic acid (C ₂₀ ), behenic acid (C ₂₂ ), tetracosane Acid (C ₂₄ ), dihexadecanoic acid (C ₂₆ ), octadecanoic acid (C ₂₈ ), tridecanoic acid (C ₃₀ ), and the like, and the isomers thereof (other than the above).

The above fatty acid may be an unsaturated fatty acid. The above unsaturated fatty acid may, for example, be a C ₃ - C ₂₀ unsaturated fatty acid such as a monounsaturated fatty acid such as crotonic acid (C ₄ ), tetradecenoic acid (C ₁₄ ) or hexadecenoic acid (C _16). ), oleic acid (C ₁₈ ), trans-octadecenoic acid (C ₁₈ ), octadecenoic acid (C ₁₈ ), eicosenoic acid (C ₂₀ ), eicosenoic acid (C ₂₀ ), etc. , diunsaturated fatty acids, such as linoleic acid (C ₁₈ ), eicosadienoic acid (C ₂₀ ), etc., triunsaturated fatty acids, such as linoleic acid, such as α-linolenic acid (C ₁₈ ) and γ- Linoleic acid (C ₁₈ ), pine nut oleic acid (C ₁₈ ), tung oil, such as α-tricoleic acid (C ₁₈ ) and β-tungonic acid (C ₁₈ ), metic acid (C ₂₀ ), di-γ-γ - linoleic acid (C ₂₀ ), eicosatrienoic acid (C ₂₀ ), etc., tetraunsaturated fatty acids, such as stearic acid (C ₂₀ ), arachidonic acid (C ₂₀ ), twenty carbon four Acetate (C ₂₀ ), etc., penta-unsaturated fatty acids, such as bosseopentaenoic acid (C ₁₈ ), eicosapentaenoic acid (C ₂₀ ), etc., and some of these hydrogen additions Things.

As the ester of the pentaerythritol and the fatty acid, it is preferable to use an ester of pentaerythritol derived from a saturated fatty acid and a fatty acid, that is, an ester of pentaerythritol and a saturated fatty acid, in consideration of the possibility of denaturation by oxidation or the like. Further, as the ester of pentaerythritol and a fatty acid, in order to make IOB smaller and more hydrophobic, a diester, a triester or a tetraester is preferred, a triester or a tetraester is more preferable, and a tetraester is more preferable.

In the above tetrakis pentaerythritol and a fatty acid tetraester, the total number of carbon atoms of the fatty acid constituting the tetraester of pentaerythritol and the fatty acid, that is, the R ¹ C, R ² C, R ³ C and R ⁴ C portions in the above formula (1) When the total carbon number is 15, the IOB becomes 0.60. Therefore, in the case where the above-mentioned pentaerythritol and the fatty acid tetraester have a total carbon number of about 15 or more, the IOB satisfies the requirements of about 0.00 to about 0.60. Examples of the above tetraester of pentaerythritol and a fatty acid include pentaerythritol and hexane acid (C ₆ ), heptanoic acid (C ₇ ), and octanoic acid (C ₈ ), for example, 2-ethylhexane acid (C ₈ ). , nonanoic acid (C _9), capric acid (C ₁₀₎ and / or lauric acid (C ₁₂₎ of the tetraester.

In the above-mentioned formula (2), the total number of carbon atoms of the R ¹ C, R ² C and R ³ C moieties is the total number of carbon atoms of the fatty acid triester of the pentaerythritol and the fatty acid. In the case of 19, the IOB became 0.58. Therefore, in the case where the total number of carbon atoms of the above-mentioned pentaerythritol and fatty acid triester and fatty acid is about 19 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.

In the above formula (3), the carbon number of the R ¹ C and R ² C moieties is 22 in total, in the case where the diester of the pentaerythritol and the fatty acid is a total of the carbon number of the fatty acid of the diester of the pentaerythritol and the fatty acid. IOB became 0.59. Therefore, in the case where the total number of carbon atoms of the above-mentioned pentaerythritol and fatty acid diester and fatty acid is about 22 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

In the monoester of pentaerythritol and a fatty acid, the carbon number of the fatty acid constituting the monoester of pentaerythritol and a fatty acid, that is, in the above formula (4), when the carbon number of the R ¹ C moiety is 25, the IOB is 0.60. Therefore, in the case where the above-mentioned pentaerythritol and a monoester of a fatty acid have a carbon number of about 25 or more, the IOB satisfies the requirements of about 0.00 to about 0.60. Also, in the above calculation, the effects of double bonds, triple bonds, iso branches, and tert branches are not considered.

The commercially available product of the ester of the pentaerythritol and the fatty acid may, for example, be UNISTAR H-408BRS or H-2408BRS-22 (mixed product) (above, manufactured by Nippon Oil Co., Ltd.).

[(a ₂ ) an ester of a chain hydrocarbon triol with at least one fatty acid]

The ester of the above chain hydrocarbon triol and at least one fatty acid can be exemplified by the following formula (5): The triglyceride of glycerol and fatty acid, the following formula (6): The diester of glycerol and fatty acid, and the following formula (7): (wherein, R ⁵ to R ⁷ are each a chain hydrocarbon) a monoester of glycerin and a fatty acid.

The fatty acid (R ⁶ COOH, R ⁶ COOH, and R ⁷ COOH) constituting the ester of the glycerin and the fatty acid, and the ester of the glycerin and the fatty acid are not particularly limited as long as the above-mentioned IOB, melting point, and water solubility are satisfied, for example, "(a ₁ ) The fatty acid exemplified in the ester of a chain hydrocarbon tetraol and at least one fatty acid, that is, a saturated fatty acid or an unsaturated fatty acid, for example, may be denatured by oxidation or the like, and may be derived from a saturated fatty acid. An ester of glycerin with a fatty acid, that is, an ester of glycerin and a saturated fatty acid is preferred.

Further, in order to make the IOB smaller and more hydrophobic, the ester of the glycerin and the fatty acid is preferably a diester or a triester, and more preferably a triester.

The above triglyceride of glycerol and fatty acid, also known as triglyceride, such as triester of glycerol and octanoic acid (C ₈ ), triester of glycerol and decanoic acid (C ₁₀ ), glycerol and dodecanoic acid (C ₁₂ a triester, and a triester of glycerin with two or three fatty acids, and mixtures thereof.

Examples of the glycerin and the triester of two or more kinds of fatty acids include triglycerides of glycerol and octanoic acid (C ₈ ) and decanoic acid (C ₁₀ ), glycerin and octanoic acid (C ₈ ), and decanoic acid ( C ₁₀ ) and the triester of dodecanoic acid (C ₁₂ ), glycerol and octanoic acid (C ₈ ), decanoic acid (C ₁₀ ), dodecanoic acid (C ₁₂ ), myristic acid (C ₁₄ ), a triester of palmitic acid (C ₁₆ ) and octadecanoic acid (C ₁₈ ).

In the above-mentioned glycerin and fatty acid triester, in order to make the melting point be lower than about 45 ° C, the carbon number of the fatty acid constituting the triester of glycerin and fatty acid is total, that is, in the formula (5), R ⁵ C, R ⁶ C and R ^The total carbon number of the ⁷ C portion is preferably about 40 or less.

Further, in the above-mentioned triglyceride of glycerin and fatty acid, the carbon number of the fatty acid constituting the triester of glycerin and fatty acid is total, that is, the total carbon number of the R ⁵ C, R ⁶ C and R ⁷ C portions in the formula (5) In the case of 12, the IOB becomes 0.60. Therefore, in the case where the total number of carbon atoms of the glycerin and the fatty acid triester and the fatty acid is about 12 or more, the IOB satisfies the requirement of about 0.00 to about 0.60. The above-mentioned triglyceride of glycerin and fatty acid is a so-called fat, and it is a component of a human body, and it is preferable from a viewpoint of safety.

The commercially available product of the above-mentioned glycerin and fatty acid triester may, for example, be tricocohol fatty acid glyceride, NA36, Panaseate 800, Panasete 800B, and Panaseate 810S, and tri-C2L oil fatty acid glyceride and tri-CL oil fatty acid glyceride (above, Nippon Oil Co., Ltd.) Company system) and so on.

The above diglycerides of glycerol and fatty acid are also called diglycerides, such as diesters of glycerol and decanoic acid (C ₁₀ ), diesters of glycerol and dodecanoic acid (C ₁₂ ), glycerol and palmitic acid (C ₁₆ a diester, and a diester of glycerin and two fatty acids, and mixtures thereof.

In the case where the glycerin and the fatty acid diester are combined with the carbon number of the fatty acid constituting the diester of the glycerin and the fatty acid, that is, in the formula (6), when the total carbon number of the R ⁵ C and R ⁶ C moieties is 16, IOB Become 0.58. Therefore, in the case where the total number of carbon atoms of the glycerin and the fatty acid diester and the fatty acid is about 16 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

The monoester of the above glycerin and fatty acid is also called a monoglyceride, for example, a monoalcoholic acid (C ₂₀ ) monoester of glycerin, a behenic acid (C ₂₂ ) monoester of glycerin or the like. In the case where the monoester of glycerin and a fatty acid constitutes a carbon number of a fatty acid which constitutes a monoester of glycerin and a fatty acid, that is, in the formula (7), when the carbon number of the R ⁵ C moiety is 19, IOB is 0.59. Therefore, in the case where the carbon number of the glycerin and the fatty acid monoester and the fatty acid is about 19 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

[(a ₃ ) an ester of a chain hydrocarbon diol with at least one fatty acid]

The ester of the chain hydrocarbon diol and at least one fatty acid may, for example, be a C ₂ -C ₆ chain hydrocarbon diol, for example, a C ₂ -C ₆ diol such as ethylene glycol, propylene glycol or butylene glycol. a monoester or diester of pentanediol or hexanediol with a fatty acid.

Specifically, the ester of the above chain hydrocarbon diol and at least one fatty acid can be exemplified by the following formula (8): R ⁸ COOC _k H _2k OCOR ⁹ (8) (wherein k is an integer of 2 to 6, and R ⁸ and R ⁹ are each a chain hydrocarbon; a diester of a C ₂ -C ₆ diol and a fatty acid, and a formula (9): R ⁸ COOC _k H _2k OH (9) (wherein k is 2 to 6) An integer of the formula, and R ⁸ is a chain hydrocarbon) of a C ₂ -C ₆ diol and a monoester of a fatty acid.

Among the above-mentioned esters of C ₂ -C ₆ diols and fatty acids, it is desired to esterify fatty acids (in the formulas (8) and (9), which are equivalent to R ⁸ COOH and R ⁹ COOH), C ₂ -C ₆ diols and fatty acids. The ester is not particularly limited as long as it satisfies the above requirements for IOB, melting point and water solubility, for example, the fatty acid listed in "(a ₁ ) chain hydrocarbon tetraol and at least one fatty acid ester", that is, saturated fatty acid and unsaturated For fatty acids, it is preferred to use saturated fatty acids in consideration of the possibility of denaturation by oxidation or the like.

When the total number of carbon atoms of the butanediol (k=4) represented by the formula (8) and the diester of the fatty acid and the R ⁸ C and R ⁹ C moieties is 6, the IOB becomes 0.60. Therefore, in the case where the butanediol (k=4) represented by the formula (8) and the diester of the fatty acid have a total carbon number of about 6 or more, the IOB satisfies the requirements of about 0.00 to about 0.60. Further, in the case of the ethylene glycol (k=2) represented by the formula (9) and the monoester of the fatty acid, and the carbon number of the R ⁸ C moiety is 12, the IOB is 0.57. Therefore, in the case of the ethylene glycol (k=2) represented by the formula (9) and the monoester of the fatty acid, and the carbon number of the fatty acid is about 12 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.

In the case of the above-mentioned ester of a C ₂ -C ₆ diol and a fatty acid, considering the possibility of denaturation by oxidation or the like, an ester of a C ₂ -C ₆ diol derived from a saturated fatty acid and a fatty acid, that is, a C ₂ -C ₆ II Esters of alcohols and saturated fatty acids are preferred.

Further, in order to make the IOB smaller and more hydrophobic, the ester of the C ₂ -C ₆ diol and the fatty acid is an ester of an alcohol and a fatty acid derived from a diol of a large carbon number, for example, from butanediol or pentane. Esters of alcohols and fatty acids of diol or hexanediol are preferred.

Further, in terms of the ester of the C ₂ -C ₆ diol and the fatty acid, in order to make the IOB smaller and more hydrophobic, a diester is preferred. The commercially available product of the above-mentioned ester of a C ₂ -C ₆ diol and a fatty acid may, for example, be a Cobopol BL or a Cotomboru BS (above, manufactured by Nippon Oil Co., Ltd.).

[(B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (B2) having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety; Ether of a hydroxy compound]

(B) (B1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (B2) 1 having a chain hydrocarbon moiety and a hydrogen atom replacing the above chain hydrocarbon moiety The ether of a hydroxy group compound (hereinafter also referred to as "compound (B)") may have an ether group which is not completely etherified by having the above-mentioned IOB, melting point and water solubility.

(B1) The compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, for example, "the compound (A)", as a compound (A1), for example, pentaerythritol, Glycerin, and diol.

(B2) a hydrogen atom having a chain hydrocarbon portion and a portion replacing the above chain hydrocarbon portion A compound having one hydroxyl group (hereinafter also referred to as "compound (B2)") may, for example, be a compound in which one hydrogen atom of a hydrocarbon is substituted with one hydroxyl group (-OH), for example, an aliphatic one. Alcohols such as saturated aliphatic monohydric alcohols and unsaturated aliphatic monohydric alcohols.

The saturated aliphatic monohydric alcohol may, for example, be a C ₁ to C ₂₀ saturated aliphatic monohydric alcohol such as methyl alcohol (C ₁ ) (C ₁ represents a carbon number, the same applies hereinafter), and ethyl alcohol (C ₂ ) , propyl alcohol (C ₃ ) and isomers thereof, such as isopropyl alcohol (C ₃ ), butyl alcohol (C ₄ ) and isomers thereof, such as sec-butyl alcohol (C ₄ ) and tert- Butanol (C ₄ ), pentyl alcohol (C ₅ ), hexyl alcohol (C ₆ ), heptyl alcohol (C ₇ ), octyl alcohol (C ₈ ) and isomers thereof, such as 2-ethylhexyl Alcohol (C ₈ ), mercapto alcohol (C ₉ ), mercapto alcohol (C ₁₀ ), dodecyl alcohol (C ₁₂ ), tetradecyl alcohol (C ₁₄ ), hexadecanol (C ₁₆ ), seventeen alcohol (C _17), octadecyl alcohol (C _18), and eicosyl alcohol (C _20), and of these isomers thereof not enumerated.

The unsaturated aliphatic monohydric alcohol may, for example, be one in which one of the CC single bonds of the above saturated aliphatic monohydric alcohol is substituted with a C=C double bond, for example, an oleyl alcohol, for example, a new Japanese physicochemical company with a Rikacol series. And the Anjie Kelu series name is sold.

The compound (B) may, for example, be an ether of a (b ₁ ) chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, such as a monoether, a diether, a triether and a tetraether, preferably a diether or a triether. And a tetraether, more preferably a triether and a tetraether, more preferably a tetraether, (b ₂ ) a chain hydrocarbon triol and an ether of at least one aliphatic monohydric alcohol, such as a monoether, a diether and a triether, preferably diether ether and three, three and more preferably an ether, and (b ₃₎ a chain hydrocarbon diol and at least one of an aliphatic monohydric alcohol ethers, monoethers and diethers, for example, and preferably two ether.

The ether of the above chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol can be exemplified by the following formulas (10) to (13): (wherein, R ¹⁰ to R ¹³ are each a chain hydrocarbon) a pentaerythritol and an aliphatic monohydric alcohol tetraether, a triether, a diether, and a monoether.

The ether of the above chain hydrocarbon triol and at least one aliphatic monohydric alcohol can be exemplified by the following formulas (14) to (16): (wherein, R ¹⁴ to R ¹⁶ are each a chain hydrocarbon) glycerol and an aliphatic monohydric alcohol triether, diether and monoether.

The ether of the above chain hydrocarbon diol and at least one aliphatic monohydric alcohol can be exemplified by the following formula (17): R ¹⁷ OC _n H _2n OR ¹⁸ (17) (wherein n is an integer of 2 to 6, and R ¹⁷ and R ¹⁸ are each a chain hydrocarbon (C ₂ -C ₆ diol) and a diester of an aliphatic monohydric alcohol, and the following formula (18): R ¹⁷ OC _n H _2n OH (18) (wherein n is an integer of 2 to 6, and R ¹⁷ is a chain hydrocarbon (C ₂ -C ₆ diol) and a monoether of an aliphatic monohydric alcohol.

In the tetraether of the pentaerythritol and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the tetraether of the pentaerythritol and the aliphatic monohydric alcohol, that is, R ¹⁰ and R ¹¹ in the above formula (10) When the total carbon number of the R ¹² and R ¹³ portions is 4, the IOB becomes 0.44. Therefore, when the total number of carbon atoms of the above-mentioned pentaerythritol and the aliphatic monohydric alcohol and the aliphatic monohydric alcohol is about 4 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

The total number of carbon atoms of the aliphatic monohydric alcohol forming the pentaerythritol and the triether of the aliphatic monohydric alcohol in the above-mentioned pentaerythritol and the aliphatic trihydric alcohol triol, that is, in the above formula (11), R ¹⁰ and R ¹¹ When the total carbon number of the R ¹² portion is 9, the IOB becomes 0.57. Therefore, in the case where the total number of carbon atoms of the above-mentioned pentaerythritol and the aliphatic trihydric alcohol and the aliphatic monohydric alcohol is about 9 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

In the diether of the pentaerythritol and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the diether of the pentaerythritol and the aliphatic monohydric alcohol, that is, R ¹⁰ and R ¹¹ in the above formula (12) When the total carbon number is 15 in total, the IOB becomes 0.60. Therefore, when the total number of carbon atoms of the above-mentioned pentaerythritol and the aliphatic dihydric alcohol and the aliphatic monohydric alcohol is about 15 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

The carbon number of the aliphatic monohydric alcohol which constitutes the monoether of pentaerythritol and the aliphatic monohydric alcohol in the monoether of the pentaerythritol and the aliphatic monohydric alcohol, that is, the carbon number of the R ¹⁰ moiety in the above formula (13) For the case of 22, the IOB becomes 0.59. Therefore, in the case where the carbon number of the above-mentioned pentaerythritol and the aliphatic monohydric alcohol and the aliphatic monohydric alcohol is about 22 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

Further, in the triether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the triether of glycerin and the aliphatic monohydric alcohol, that is, R ¹⁴ and R in the formula (14) ^{When the} total carbon number of the ¹⁵ and R ¹⁶ portions is 3, the IOB becomes 0.50. Therefore, when the total number of carbon atoms of the glycerin and the aliphatic trihydric alcohol and the aliphatic monohydric alcohol is about 3 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

In the diether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the diether of the glycerin and the aliphatic monohydric alcohol, that is, the R ¹⁴ and R ¹⁵ portions in the formula (15) When the total carbon number is 9, the IOB becomes 0.58. Therefore, in the case where the total number of carbon atoms of the glycerin and the aliphatic dihydric alcohol and the aliphatic monohydric alcohol is about 9 or more, the IOB satisfies the requirements of about 0.00 to about 0.60.

In the monoether of the glycerin and the aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the monoether of the glycerin and the aliphatic monohydric alcohol, that is, in the formula (16), the carbon number of the R ¹⁴ moiety is On the 16th occasion, the IOB became 0.58. Therefore, in the case where the carbon number of the monoglyceride of the glycerin and the aliphatic monohydric alcohol and the aliphatic monohydric alcohol is about 16 or more, the IOB satisfies the requirement of about 0.00 to about 0.60.

When the total number of carbon atoms of the diphenyl diol (n = 4) represented by the formula (17) and the diester of the aliphatic monohydric alcohol and the R ¹⁷ and R ¹⁸ portions is 2, the IOB is 0.33. Therefore, when the total number of carbon atoms of the butanediol (n=4) represented by the formula (17) and the diester of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol is 2 or more, the IOB satisfies about 0.00 to about 0.60. The essentials. Further, in the case of the ethylene glycol (n = 2) represented by the formula (18) and the monoether of the aliphatic monohydric alcohol, when the carbon number of the R ¹⁷ moiety is 8, the IOB is 0.60. Therefore, in the case where the ethylene glycol (n=2) represented by the formula (18) and the monoether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol have a carbon number of about 8 or more, the IOB satisfies about 0.00 to about 0.60. The essentials.

Compound (B) by combining compound (B1) with compound The substance (B2) is produced by dehydration condensation in the presence of an acid catalyst.

[(C)(C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or a oxo acid having a chain hydrocarbon moiety and 2 to 4 carboxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (C2) have a chain shape An ester of a hydrocarbon moiety and a compound substituted with one hydroxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety]

(C) (C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or a pendant oxyacid having a chain hydrocarbon moiety and 2 to 4 carboxyl groups which replace the hydrogen atom of the above-mentioned chain hydrocarbon moiety, and (C2) having a chain hydrocarbon An ester of a compound partially substituted with one hydroxyl group of a hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter also referred to as "compound (C)") may have a carboxyl group which may have a carboxyl group having a melting point and a water solubility as described above. Esterification.

(C1) a carboxylic acid, a hydroxy acid, an alkoxy acid or a side oxyacid containing a chain hydrocarbon moiety and a 2-4 carboxyl group which replaces the hydrogen atom of the above-mentioned chain hydrocarbon moiety (hereinafter, also referred to as "compound (C1)" In the case of the above, for example, a chain hydrocarbon carboxylic acid having 2 to 4 carboxyl groups, for example, a chain hydrocarbon dicarboxylic acid such as an alkanedicarboxylic acid such as ethanedioic acid, propane diacid or butanedioic acid, Pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, decanedioic acid and decanedioic acid, chain hydrocarbon tricarboxylic acid, such as an alkane tricarboxylic acid, such as propane triacid, butane Triacid, pentanetricarboxylic acid, hexanetricarboxylic acid, heptanetricarboxylic acid, octanetricarboxylic acid, decanetricarboxylic acid and decanetricarboxylic acid, and chain hydrocarbon tetracarboxylic acid, such as an alkanetetracarboxylic acid, such as butane Tetraacid, pentanetetracarboxylic acid, hexanetetracarboxylic acid, heptanetetracarboxylic acid, octane tetracarboxylic acid, decanetetracarboxylic acid, and decanetetracarboxylic acid.

Further, the compound (C1) contains 2 to 4 carboxyl groups. Chain hydrocarbon hydroxy acid, such as malic acid, tartaric acid, citric acid, isocitric acid, etc., a chain hydrocarbon alkoxy acid having 2 to 4 carboxyl groups, such as O-ethyl citrate, and having 2 to 4 a carboxyl group-like hydrocarbon side acid.

(C2) The compound having a chain hydrocarbon moiety and a hydroxyl group which replaces the hydrogen atom of the chain hydrocarbon moiety, for example, those listed in "Compound (B)", for example, an aliphatic monohydric alcohol.

The compound (C) may, for example, be (c ₁ ) an ester of a chain hydrocarbon tetracarboxylic acid having four carboxyl groups, a hydroxy acid, an alkoxy acid or a side acid and at least one aliphatic monohydric alcohol, for example, a monoester. , diester, triesters and tetraesters, preferably diesters, triesters and tetraesters, more preferably triesters and triesters, more preferably tetraesters, (c ₂ ) chain hydrocarbons having 3 carboxyl groups An ester of a carboxylic acid, a hydroxy acid, an alkoxy acid or a pendant acid with at least one aliphatic monohydric alcohol, such as a monoester, a diester and a triester, preferably a diester and a triester, and more preferably three. And an ester of (c ₃ ) a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or a oxo acid with at least one aliphatic monohydric alcohol, such as a monoester or a diester, Jia is a diester.

Examples of the compound (C) include commercially available products such as dioctyl adipate, tributyl butyl ethoxide and the like.

[(D) an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-) having a chain hydrocarbon moiety and a CC single bond intercalated with the above chain hydrocarbon moiety, and a compound selected from a group of carbonate linkages (-OCOO-)]

(D) an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-), and a carbonic acid having a chain hydrocarbon moiety and a CC single bond intercalated with the above chain hydrocarbon moiety Any of the compounds selected in the group in which the ester bond (-OCOO-) is selected (hereinafter, also referred to as "compound (D)"), for example, (d ₁ ) aliphatic monohydric alcohol and fat An ether of a monohydric alcohol, a (d ₂ ) dialkyl ketone, an ester of a (d ₃ ) fatty acid and an aliphatic monohydric alcohol, and (d ₄ ) a dialkyl carbonate.

[(d ₁ ) an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol]

The ether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol may, for example, be a compound having the following formula (19): R ¹⁹ OR ²⁰ (19) (wherein each of R ¹⁹ and R ²⁰ is a chain hydrocarbon).

In the case of the aliphatic monohydric alcohol (equivalent to R ¹⁹ OH and R ²⁰ OH in the formula (19)), the ether is not particularly limited as long as it satisfies the above-mentioned requirements for IOB, melting point and water solubility, and for example, The aliphatic monohydric alcohol exemplified in the compound (B).

In the ether of the aliphatic monohydric alcohol and the aliphatic monohydric alcohol, the total number of carbon atoms of the aliphatic monohydric alcohol constituting the ether, that is, in the above formula (19), the total carbon number of the R ¹⁹ and R ²⁰ moieties is In the case of 2, since the IOB is 0.50, the total number of carbon atoms is about 2 or more, and the requirements of the above IOB are satisfied. However, the total carbon number is about 6, and the water solubility is about 2 g higher, which is also problematic from the viewpoint of vapor pressure. In order to satisfy the requirement that the water solubility is from about 0.00 to about 0.05 g, the total carbon number is preferably about 8 or more.

[(d ₂ )dialkyl ketone]

The dialkyl ketone may, for example, be a compound having the following formula (20): R ²¹ COR ²² (20) (wherein each of R ²¹ and R ²² is an alkyl group).

In the case where the total number of carbon atoms of R ²¹ and R ²² is 5, the IOB is 0.54. Therefore, if the total number of carbon atoms is about 5 or more, the requirements of the above IOB are satisfied. However, the total carbon number is about 5, and the water solubility is as high as about 2 g. Therefore, in order to satisfy the requirement that the water solubility is from about 0.00 to about 0.05 g, it is preferred that the total carbon number is about 8 or more. Further, when the vapor pressure is considered, the carbon number is preferably about 10 or more, and more preferably about 12 or more.

Further, when the total carbon number is about 8, for example, 5-nonanone has a melting point of about -50 ° C and a vapor pressure of about 230 Pa at 20 ° C.

The above dialkyl ketone can be obtained by a conventional method, for example, by oxidizing a second-stage alcohol with chromic acid or the like, in addition to a commercially available one.

[(d ₃ ) ester of fatty acid with aliphatic monohydric alcohol]

The ester of the fatty acid and the aliphatic monohydric alcohol may, for example, be a compound having the following formula (21): R ²³ COOR ²⁴ (21) (wherein each of R ²³ and R ²⁴ is a chain hydrocarbon).

The fatty acid constituting the above-mentioned ester (corresponding to R ²³ COOH in the formula (21)) may, for example, be a fatty acid as exemplified in the "(a ₁ ) chain hydrocarbon tetraol and at least one fatty acid ester", that is, a saturated fatty acid. Or unsaturated fatty acids, if considering the possibility of denaturation by oxidation, etc., it is preferable to use a saturated fatty acid. The aliphatic monohydric alcohol (e.g., R ²⁴ OH in the formula (21)) constituting the above-mentioned ester may, for example, be an aliphatic monohydric alcohol as exemplified in the "compound (B)".

In addition, in the case where the carbon number of the fatty acid and the aliphatic monohydric alcohol, the fatty acid and the aliphatic monohydric alcohol are in total, that is, in the formula (21), the total carbon number of the R ²³ C and R ²⁴ moieties is 5 When the IOB is 0.60, the total number of carbon atoms in the R ²³ C and R ²⁴ portions is about 5 or more, and the requirements of the above IOB are satisfied. However, for example, in the case of the above-mentioned butyl acetate having a total carbon number of 6, the vapor pressure is as high as more than 2,000 Pa. Therefore, in consideration of the vapor pressure, it is preferred that the total carbon number is about 12 or more. Moreover, when the total carbon number is about 11 or more, the water solubility is about 0.00 to about 0.05 g.

Examples of the ester of the above fatty acid and the aliphatic monohydric alcohol include, for example, an ester of dodecanoic acid (C ₁₂ ) and dodecyl alcohol (C ₁₂ ), myristic acid (C ₁₄ ) and dodecyl alcohol (C _{12 ).} For example, the ester of the above-mentioned fatty acid and the ester of the aliphatic monohydric alcohol may, for example, be an Aurelu WE20 or an Ailelu WE40 (above, manufactured by Nippon Oil Co., Ltd.).

[(d ₄ )Dialkyl carbonate]

The dialkyl carbonate may, for example, be a compound having the following formula (22): R ²⁵ OC(=O)OR ²⁶ (22) (wherein each of R ²⁵ and R ²⁶ is an alkyl group).

In the case where the total number of carbon atoms of R ²⁵ and R ²⁶ is 6 in the above dialkyl carbonate, the IOB is 0.57. Therefore, the total carbon number of R ²⁵ and R ²⁶ is about 6 or more to satisfy the requirements of IOB.

When the water solubility is considered, the total carbon number of R ²⁵ and R ²⁶ is preferably about 7 or more, and more preferably about 9 or more.

The above dialkyl carbonates can be synthesized by the reaction of phosgene with an alcohol, the reaction of a chlorinated formate with an alcohol or an alkoxide, and the reaction of silver carbonate with an alkyl iodide, in addition to those commercially available.

[(E) Polyoxygenated C ₂ ~C ₆ alkanediol, or its ester or ether]

The polyoxy C ₂ -C ₆ alkanediol, or an ester or ether thereof (hereinafter, in the case of the compound (E)), for example, (e ₁ ) a polyoxygenated C ₂ -C ₆ alkanediol, (e ₂ ) Polyoxy-C ₂ -C ₆ alkanediol with at least one fatty acid ester, (e ₃ ) polyoxygenated C ₂ -C ₆ alkanediol and at least one aliphatic monohydric alcohol ether, (e ₄ ) polyoxidation An ester of a C ₂ -C ₆ alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid, or a chain hydrocarbon dicarboxylic acid, and (e ₅ ) a polyoxygenated C ₂ -C ₆ alkanediol and a chain An ether of a hydrocarbon tetraol, a chain hydrocarbon triol, or a chain hydrocarbon diol. The following description will be made.

[(e ₁ ) Polyoxygenated C ₂ ~C ₆ alkanediol]

The above polyoxygenated C ₂ -C ₆ alkanediol refers to i) having an oxidized C ₂ -C ₆ alkene skeleton, that is, an oxyethylene skeleton, an oxypropylene skeleton, a butylene oxide skeleton, a pentene oxide skeleton, and oxidation. a homopolymer having a skeleton selected from the group consisting of a hexene skeleton and having a hydroxyl group at both terminals, ii) a block copolymer having two or more kinds of skeletons selected from the above group and having a hydroxyl group at both terminals, Or iii) a random copolymer having two or more kinds of skeletons selected from the above group and having a hydroxyl group at both terminals.

The oxidized C ₂ -C ₆ alkene skeleton preferably has an oxypropylene skeleton, a oxidized butene skeleton, a pentylene skeleton, or a hexene oxide skeleton from the viewpoint of lowering the IOB of the polyoxygen C ₂ -C ₆ alkanediol. The butylene oxide skeleton, the pentene oxide skeleton or the oxyhexene skeleton is more preferable.

The polyoxygenated C ₂ -C ₆ alkanediol can be represented by the following formula (23): HO-(C _m H _2m O) _n -H (23) (wherein m is an integer of 2 to 6).

Moreover, the inventors of the present invention confirmed that polyethylene glycol (a homopolymer equivalent to m=2 in the formula (23)) satisfies about n:45 (weight average molecular weight is more than about 2,000). 0.00 to about 0.60 of the requirements of the IOB, but even in the case where the weight average molecular weight exceeds about 4,000, the water solubility requirement is not satisfied. Therefore, the (e ₁ ) polyoxygenated C ₂ -C ₆ alkanediol does not contain a homopolymer of ethylene glycol, and the ethylene glycol is used as a block copolymer or a random copolymer with other diols, and is contained in (e ₁ ) a polyoxygenated C ₂ ~C ₆ alkanediol.

Therefore, the homopolymer of the formula (23) may contain a homopolymer of propylene glycol, butylene glycol, pentanediol or hexanediol.

From the above, in the formula (23), m is from about 3 to about 6, more preferably from about 4 to about 6, and further preferably n is 2 or more.

In the above formula (23), the value of n is a polyoxygenated C ₂ -C ₆ alkanediol having an IOB of from about 0.00 to about 0.60, a melting point of about 45 ° C or less, and a water content of from about 0.00 to about 0.05 g per 100 g of water at 25 ° C. The value of the water solubility.

For example, when the formula (23) is polypropylene glycol (m=3 homopolymer), when n=12, IOB is 0.58. Therefore, when the formula (23) is a polypropylene glycol (m=3 homopolymer), when m≧ is about 12, the requirements of the above IOB are satisfied.

Further, when the formula (21) is polytetramethylene glycol (m=4 homopolymer), when n=7, IOB is 0.57. Therefore, when the formula (23) is polytetramethylene glycol (m=4 homopolymer), when n≧ is about 7, the requirements of the above IOB are satisfied.

The weight average molecular weight of the polyoxygenated C ₂ -C ₆ alkanediol is preferably from about 200 to about 10,000, more preferably from about 250 to about 8,000, still more preferably from about 250, from the viewpoints of IOB, melting point and water solubility. ~ A range of about 5,000.

Further, from the viewpoints of IOB, melting point and water solubility, the weight average molecular weight of the polyoxygenated C ₃ alkanediol, i.e., polypropylene glycol, is preferably from about 1,000 to about 10,000, more preferably from about 3,000 to about 8,000, still more. Good is in the range of about 4,000 to about 5,000. Since the above weight average molecular weight is less than about 1,000, the water solubility is not satisfactory, and the weight average molecular weight is larger, in particular, the moving speed of the absorbent and the whiteness of the top sheet tend to increase.

Commercial products of the above polyoxidized C ₂ -C ₆ alkanediol include, for example, Uniol (trademark) D-1000, D-1200, D-2000, D-3000, D-4000, PB-500, PB-700. , PB-1000 and PB-2000 (above, manufactured by Nippon Oil Co., Ltd.).

[(e ₂ ) an ester of polyoxygenated C ₂ ~C ₆ alkanediol with at least one fatty acid]

The above-described polyoxyalkylene C ₂ ~ C ₆ alkylene glycol and at least one ester of a fatty acid includes, for example, "(e ₁₎ polyoxy C ₂ ~ C ₆ alkanediol" section described polyoxyalkylene C ₂ ~ C ₆ alkyl One or both of the OH ends of the diol are esterified with fatty acids, i.e., monoesters and diesters.

In the ester of a polyoxygenated C ₂ -C ₆ alkanediol and at least one fatty acid, the fatty acid is to be esterified, and examples thereof include "(a ₁ ) chain hydrocarbon tetraol and at least one fatty acid ester". A fatty acid, that is, a saturated fatty acid or an unsaturated fatty acid, is preferably a saturated fatty acid if it is considered to be modified by oxidation or the like.

A commercially available product of the above-mentioned ester of a polyoxygenated C ₂ -C ₆ alkanediol and a fatty acid is, for example, WILBRIDE cp9 (manufactured by Nippon Oil Co., Ltd.).

[(e ₃ ) an ether of a polyoxygenated C ₂ -C ₆ alkanediol and at least one aliphatic monohydric alcohol]

The above-described polyoxyalkylene C ₂ ~ C ₆ alkylene glycol and at least one aliphatic ethers of monohydric alcohol includes, for example, "(e ₁₎ polyoxy C ₂ ~ C ₆ alkanediol" section described polyoxyalkylene C ₂ ~ OH terminus of one or both C ₆ alkanediol by aliphatic monohydric alcohol etherified by, i.e., monoethers and diethers.

In the ether of the polyoxygenated C ₂ -C ₆ alkanediol and the at least one aliphatic monohydric alcohol, the aliphatic monohydric alcohol to be etherified may, for example, be an aliphatic 1 as exemplified in the "compound (B)". Alcohol.

[(e ₄ ) an ester of a polyoxygenated C ₂ -C ₆ alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid, or a chain hydrocarbon dicarboxylic acid]

The above-mentioned ester of a polyoxygenated C ₂ -C ₆ alkanediol with a chain hydrocarbon tetracarboxylic acid, a chain hydrocarbon tricarboxylic acid, or a chain hydrocarbon dicarboxylic acid, to esterify a polyoxygenated C ₂ -C ₆ alkanediol includes, for example, "(e ₁₎ polyoxy C ₂ ~ C ₆ alkanediol" section described polyoxyalkylene C ₂ ~ C ₆ alkanediol. Further, the chain hydrocarbon tetracarboxylic acid, the chain hydrocarbon tricarboxylic acid, and the chain hydrocarbon dicarboxylic acid are preferably esterified, and examples thereof include those described in "(Compound (C)".

The polyoxy C ₂ -C ₆ alkanediol and the chain hydrocarbon tetracarboxylic acid, the chain hydrocarbon tricarboxylic acid, or the chain hydrocarbon dicarboxylic acid ester may be a chain hydrocarbon tetracarboxylic acid, in addition to a commercial product. The chain hydrocarbon tricarboxylic acid or the chain hydrocarbon dicarboxylic acid is produced by polycondensation of an oxidized C ₂ -C ₆ alkanediol under a known condition.

[(e ₅ ) polyoxygenated C ₂ -C ₆ alkanediol and chain hydrocarbon tetraol, chain hydrocarbon triol, or ether of chain hydrocarbon diol]

The above-described polyoxyalkylene C ₂ ~ C ₆ alkylene glycol and a chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol of the ether to be etherified polyoxyalkylene C ₂ ~ C ₆ alkylene glycol, may be Examples such as "(e ₁₎ polyoxy C ₂ ~ C ₆ alkanediol" section described polyoxyalkylene C ₂ ~ C ₆ alkanediol. Further, examples of the chain hydrocarbon tetraol, the chain hydrocarbon triol, and the chain hydrocarbon diol to be etherified include those described in the section "(Compound (A)", such as pentaerythritol, glycerin, and diol.

Commercial products of the above-mentioned polyoxy C ₂ -C ₆ alkanediol and a chain hydrocarbon tetraol, a chain hydrocarbon triol, or a chain hydrocarbon diol are exemplified by UNILUBE (trademark) 5TP-300KB, and Uniol. (Trademark) TG-3000 and TG-4000 (made by Nippon Oil Co., Ltd.).

UNILUBE (Trade Mark) 5TP-300KB is a compound which polycondenses pentaerythritol 1 molar with propylene glycol 65 mole and ethylene glycol 5 mole, and has an IOB of 0.39, a melting point of less than 45 ° C, and a water solubility of less than 0.05 g.

Uniol (trademark) TG-3000 is a compound in which 50 mer of glycerol 1 molar and propylene glycol 50 is condensed, and has an IOB of 0.42, a melting point of less than 45 ° C, a water solubility of less than 0.05 g, and a weight average molecular weight of about 3,000.

Uniol (trademark) TG-4000 is a compound in which glycerol 1 molar is condensed with propylene glycol 70, having an IOB of 0.40, a melting point of less than 45 ° C, a water solubility of less than 0.05 g, and a weight average molecular weight of about 4,000.

The above-mentioned polyoxy C ₂ -C ₆ alkanediol and an ether of a chain hydrocarbon tetraol, a chain hydrocarbon triol or a chain hydrocarbon diol can be further obtained by chain hydrocarbon tetraol, chain hydrocarbon triol, Alternatively, the chain hydrocarbon diol is added to a C ₂ -C ₆ alkylene oxide under conventional conditions.

[(F) chain hydrocarbon]

The chain hydrocarbon may be contained in the blood modifying agent because the inorganic value is 0, the IOB is 0.00, and the water solubility is about 0 g. Therefore, the melting point is about 45 ° C or lower. The chain hydrocarbon may, for example, be a (f ₁ ) chain alkane, for example, a linear alkane or a branched alkane. For example, in the case of a linear alkane, when the melting point is about 45 ° C or less, the carbon number is preferably 22 or less. Further, when the vapor pressure is considered, it is likely to contain a carbon number of 13 or more. In the case of a branched paraffin, since the melting point is low in the same carbon number as the linear alkane, it is also possible to include a carbon number of 22 or more.

A commercially available product of the above hydrocarbons may, for example, be PARLEAM 6 (Nippon Oil Co., Ltd.).

The above blood modifying agent was examined in detail together with the examples, and it was found to have at least a function of lowering blood viscosity and surface tension. The menstrual blood to be absorbed by the absorbent article is compared with the general blood, and the blood cells are connected to each other by the proteins such as the endometrial wall, and the blood cells are easily in a state of continuous alignment. Therefore, the menstrual blood to be absorbed by the absorbent article tends to become highly viscous, and when the top sheet is non-woven or woven, the menstrual blood tends to block between the fibers, and the user tends to feel sticky, and the surface of the top sheet diffuses through the blood. It becomes easy to leak.

Further, since the blood modifying agent having an IOB of about 0.00 to about 0.60 is highly organic and easily penetrates into the blood cells, the blood cells are stabilized and the blood cells are less likely to form a linked structure.

The above-mentioned modifier can make the blood cells stable, and the blood cells are less likely to form a linked structure, and the absorbent body can easily absorb menstrual blood. For example, it is known that in an absorbent article containing an acrylic high-absorbent polymer and a so-called SAP, when menstrual blood is absorbed, the linked blood cells coat the surface of the SAP, and the SAP becomes difficult to exhibit absorption performance, but by making the blood cells stable, SAP becomes Easy to play absorption performance. also because A blood modifying agent having high affinity with red blood cells protects the red blood cell membrane, and the red blood cells become difficult to be destroyed.

Fig. 5 is a view for explaining the absorbent article 1 in which the wings 6 are folded for packaging. When the absorbent article 1 having the above constituent elements is packaged, as shown in Fig. 5, the pair of wing portions 6 are folded inward in the width direction.

The adhesive portion 7 is covered with a release sheet 33. Thereby, the adhesive portion 7 before use of the absorbent article 1 can be protected. The release sheet 33 is not particularly limited as long as it can be peeled off by the adhesive of the adhesive portion 7. In the release sheet 33, for example, a release agent may be applied to the substrate. Examples of the substrate to which the release agent is applied include a film of polypropylene, low-density polyethylene, polyvinyl alcohol, a nonwoven fabric, paper, etc., and the release agent is an anthrone-based, fluorine-based or isocyanate.

As shown in Fig. 5, when the absorbent article 1 is packaged, the folded absorbent article 1 of the wing portion 6 is placed on the packaging material 31. The packaging material 31 is produced, for example, by a resin film, a nonwoven fabric, or the like. Further, a fixing adhesive tape 32 is provided at one end of the packaging material 31 in the longitudinal direction. The absorbent article 1 disposed on the packaging material 31 is folded along the B-B line and the C-C line in the longitudinal direction (Y direction) together with the packaging material 31. On the other hand, the state in which the absorbent article 1 is folded is maintained by the adhesive tape 32. On the other hand, the both sides 31a in the width direction of the packaging material 31 folded together with the absorbent article 1 are joined by heat embossing. Thereby, the package 30 shown in FIG. 6 containing the absorbent article 1 is produced. Figure 6 is a perspective view of a package 30 containing an absorbent article.

Fig. 7 is a schematic cross-sectional view showing the line D-D of Fig. 5; Figure As shown in Fig. 7, the top sheet 2 of the wing portion 6 when the wing portion 6 is folded is brought into contact with the top sheet 2 of the drain opening contact region 16 (see Figs. 1 and 2 for reference). The top sheet 2 in the wing portion 6 is in contact with the blood modifying agent layer 24 because the top layer 2 of the excretory opening contact area 16 forms the blood modifying agent layer 24. However, the contact area between the top sheet 2 and the blood modifying agent layer 24 in the wing portion 6 is small due to the first mountain fold portion 21 and/or the second mountain fold portion 22. Further, the top sheet 2 in the wing portion 6 is not formed with an opening portion. Thereby, the blood modifying agent of the blood modifying agent layer 24 can be prevented from penetrating into the wing portion 6, and the joining force between the top sheet 2 and the back sheet 3 in the wing portion 6 can be weakened. Further, it is possible to suppress the blood modifying agent of the blood modifying agent layer 24 from being transferred to the top sheet 2 of the wing portion 6 and the blood modifying agent layer 24 of the blood modifying agent layer 24 formed on the top sheet 2 of the excretory opening contact region 16. The amount is reduced.

The sealing portion 9 is formed by the edge portion in the width direction outer side of the wing portion 6 in which the first mountain fold portion 21 and/or the second mountain fold portion 22 are provided, so that the edge of the wing portion 6 can be formed as shown in FIG. 62 (Figs. 1 and 2 for reference) is separated from the top sheet 2 of the drain port contact region 16 where the blood modifying agent layer is formed. Thereby, the blood modifying agent which permeates the blood modifier layer 24 between the top sheet 2 and the back sheet 3 of the end 62 of the wing portion 2 can be suppressed, and the bonding force between the top sheet 2 and the back sheet 3 in the wing portion 2 is weakened. .

Further, since the first mountain fold portion 21 is provided on the top sheet 2 of the drain opening contact region 16 in which the blood modifying agent layer is formed, the contact area of the top sheet 2 and the blood modifying agent layer 24 in the wing portion 6 becomes smaller. . Thereby, the blood modifying agent infiltration of the wing portion 6 of the blood modifying agent layer 24 can be further suppressed, and the bonding force between the top sheet 2 and the back sheet 3 in the wing portion 6 is weakened. Further, it is possible to suppress the blood modifying agent of the blood modifying agent layer 24 from being transferred to the top sheet 2 of the wing portion 6 and the blood modifying agent layer 24 of the blood modifying agent layer 24 formed on the top sheet 2 of the excretory opening contact region 16. The amount is reduced.

Next, a method of manufacturing the absorbent article 1 according to an embodiment of the present invention will be described with reference to Fig. 8 . FIG. 8 is a view for explaining an absorbent article manufacturing apparatus 100 used in the method of manufacturing the absorbent article 1 according to the embodiment of the present invention. The method for producing the absorbent article 1 includes a step of forming an absorbent body, a step of preparing a sheet for top sheet, a step of forming a compressed groove in the laminate, a step of preparing a sheet for back sheet, and a step of cutting a continuous body of the absorbent article. The step of applying a blood modifying agent to the absorbent article. In addition, the sheet for the top sheet used in the step of preparing the sheet for the top sheet includes the step of preparing the resin film sheet, the step of forming the concave portion in the resin film sheet, and the sheet for the top sheet for the step of extending the resin film sheet. Manufacturing method to manufacture.

In the step of forming the absorber, the absorber 128 is formed on the conveyor belt 110. The pulverized pulp 122 is supplied to the pattern cylinder 120 from a pulverized pulp supply device (not shown). A concave portion 124 as a model for loading the pulverized pulp is formed on the outer peripheral portion of the pattern cylinder 120. The inside of the pattern cylinder 120 is attracted 126, and the pulverized pulp 122 supplied to the pattern cylinder 120 is sucked into the concave portion 124 to be compressed. In the recess 124, the pulp 122 is shaped as an absorber 128. The absorbent body 128 is placed on a conveyor belt.

In the step of preparing the top sheet sheet, the top sheet sheet 216 produced by the method for producing the top sheet sheet described later is placed on the absorber 128, and the top sheet sheet 216 is attached to the absorber 128. With.

In the step of forming the compression groove in the laminate, the embossing device 130 is used to form the compression groove in the top sheet sheet 216 and the laminate 262 of the absorber 128. The laminate 262 passes between the upper roller 131 and the lower roller 132 of the embossing processing device 130. A convex portion (not shown) corresponding to the shape of the compression groove 8 of the absorbent article 1 shown in Fig. 1 is provided on the outer circumferential surface of the upper roller 131. The lower stage roller 132 is a flat roll having a smooth outer peripheral surface. The portion of the laminate 262 corresponding to the compression groove 8 of the absorbent article 1 shown in FIG. 1 is compressed in the thickness direction by the laminate 262 between the upper roller 131 and the lower roller 132 of the embossing processing device 130, and the compression groove is compressed. Formed on the laminate 262.

In the step of preparing the sheet for the back sheet, the sheet for back sheet 142 supplied from the sheet roll 140 for back sheeting is applied by a coating device (not shown), and the adhesive is applied, and then laminated to the laminate 134 in which the compression groove is formed. The top sheet is formed on the side opposite the side of the sheet to form a continuous body 144 of absorbent article.

In the step of cutting the continuous body of the absorbent article, the continuous body 144 of the absorbent article is cut into the shape of the absorbent article using the cutter 150 to produce an absorbent article.

In the step of applying the blood modifying agent to the absorbent article, the sprayer 160 is coated with a modifier, and the blood modifying agent 161 is applied to the central region of the absorbent article to form blood on the surface of the excretory contact area of the top sheet. Modifier layer.

After the step of cutting the continuous body of the absorbent article, coating Although the blood modifying agent is used, the blood modifying agent may be applied in the production step of the top sheet for a sheet to be described later. In order to prevent the absorbent article from being detached from the absorbent article during the manufacture of the absorbent article, the blood modifying agent is applied to the absorbent article at a downstream stage of the manufacturing step of the absorbent article, for example, before packaging the absorbent article. good.

In the method of producing the absorbent article 1, the step of forming the adhesive portion in the continuous body 144 of the absorbent article and the step of forming the sealed portion in the continuous body 144 of the absorbent article are also included. Moreover, the manufactured absorbent article 1 is packaged using the above-mentioned packaging material.

Next, a method of manufacturing the sheet for the top sheet will be described.

In the step of preparing the resin film sheet, the resin film sheet 212 supplied from the roll 210 of the resin film sheet is supplied to the concave portion forming roll 220 as shown in FIG.

In the step of forming the concave portion in the resin film sheet, the resin film sheet 212 is passed through the concave portion forming roller 220, and the resin film sheet 214 in which the concave portion 2141 is formed is produced (see FIG. 10 for reference). The recess forming roller 220 is composed of an embossing roller 221 and a preheating roller 222 having a smooth surface.

9(a) and 9(b) are views showing an example of the embossing roll 221. Fig. 9(a) is a view showing the entirety of the embossing roll 221, and Fig. 9(b) is a view showing the enlarged portion 223 of the outer peripheral surface of the embossing roll 221. Fig. 9(c) is a view showing an example of the preheating roller 222 having a smooth surface. On the surface 223 of the embossing roll 221, a lattice-like convex portion 224 is provided. Thereby, the surface of the embossing roll 221 forms a rhombic recess 225. Moreover, the shape of the concave portion 225 of the embossing roller 221 is not limited to a diamond shape, and may be square, rectangular, or parallel. Shapes such as a triangle, a trapezoid, a triangle, a hexagon, and the like.

In the lattice-like convex portion 224, the center line spacing of the convex portions 224 arranged in parallel, that is, the pitch of the lattice-shaped convex portions 224 is preferably 0.2 mm or more and 10 mm or less, more preferably 0.4 mm or more and 2 mm or less. When the pitch of the lattice-like convex portions 224 is less than 0.2 mm or larger than 10 mm, the concave portion may not be formed in the resin film. Further, the width of the lattice-like convex portion 224 is preferably 0.01 mm or more and 1 mm or less, more preferably 0.03 mm or more and 0.1 or less. Further, the length of one side of the rhombic recess 225 is preferably 0.1 mm or more and 5 mm or less, more preferably 0.2 mm or more and 1 mm or less. When the width of the lattice-shaped convex portion 224 is less than 0.01 mm or larger than 1 mm, or the length of one side of the concave portion 225 of the rhombic shape is less than 0.1 mm or larger than 5 mm, the concave portion may not be formed in the resin film.

The preheating roll 222 having a smooth surface is maintained at a temperature of 70 ° C or more and 100 ° C or less, and the supplied resin film sheet 212 is heated. Thereby, the resin film sheet 212 becomes soft and can be easily formed.

When the resin film sheet 212 passes between the embossing roll 221 and the roller 222 having a smooth surface, the resin film sheet 212 receives a strong pressure in the thickness direction at a portion in contact with the lattice-like convex portion 224. Thereby, as shown in FIG. 10, a thin concave portion 2141 is formed in the resin film sheet 214. Further, actually, the concave portion 2141 formed on the resin film sheet 212 is smaller than that shown in Fig. 10, and the number of the concave portions 2141 per unit area is larger than that shown in Fig. 10 . The recess 2141 is formed only in the range 2143 of the resin film sheet 214 corresponding to the region 12 of the body portion 10 on which the absorber 4 is provided (see FIG. 1 for reference). Here, the range corresponding to the absorbent article 1 in the resin film sheet 214 is a range indicated by a broken line of the symbol 2142.

In the step of extending the resin film sheet, as shown in FIG. 8, the resin film sheet 214 having the concave portion is passed through the extending tooth roll 230, so that the first mountain portion and the second mountain portion of the top sheet 2 are The valley fold is formed on the resin film sheet 214. Reference numeral 216 is a resin film sheet on which the first mountain fold portion, the second mountain fold portion, and the valley fold portion are formed.

The extending tooth roll 230 includes an upper roll 231 and a lower roll 232. Fig. 11 (a) is a view for explaining the upper roller 231 of the extension tooth roller 230, and Fig. 11 (b) is a view for explaining the gear teeth 233 disposed on the outer circumferential surface of the upper roller 231, and Fig. 11 (c) is Fig. 11 (b) is a sectional view taken along line EE. The gear teeth 233 extend discontinuously in the circumferential direction of the upper roller 231. That is, the gear teeth 233 extending in the circumferential direction of the upper roller 231 are cut at a plurality of points in the middle. The second mountain fold portion is formed on the resin film sheet 214 by the cut portion 234 in the middle of the gear tooth 233.

The gear teeth 233 are, for example, 0.3 mm or more and 0.5 mm or less in width, and the distance between the centers of the adjacent gear teeth 233 is, for example, 1.0 mm or more and 1.2 mm or less.

Fig. 12 (a) is a view for explaining the lower roller 232 of the extension roller 230, and Fig. 12 (b) is a view for explaining the gear teeth 235 disposed on the outer circumferential surface of the lower roller 232, and Fig. 12 (c) is Fig. 12 (b) is a cross-sectional view taken along the line FF. The gear teeth 235 extend in the circumferential direction of the lower roller 232. The lower roller 232 is not interrupted at the plurality of places on the way as the upper roller 231. The width of the gear teeth 235 is, for example, equal to the width of the gear teeth 233 of the upper roller 231, and the phase The distance between the centers of the adjacent gear teeth 235 is, for example, equal to the distance between the centers of the gear teeth 233 of the upper roller 231.

The gear teeth 233 of the upper roller 231 and the gear teeth 235 of the lower roller 232 engage the length of the upper roller 231 in the radial direction, that is, the nip depth is, for example, 1.25 mm. The gap between the gear teeth 233 of the upper roller 231 and the gear teeth 235 of the lower roller 232 when the gear teeth 233 of the upper roller 231 are engaged with the gear teeth 235 of the lower roller 232 is, for example, 0.25 mm or more and 0.45 mm or less.

As shown in FIG. 8, when the resin film sheet 214 is extended by the tooth roll 230, the resin film 214 is bent into a slight wave shape, and the resin film 214 forms the first mountain fold portion 21 of the top sheet 2, the second mountain fold portion 22, and Valley folds 23. Further, the region 2143 of the resin film sheet 214 in which the concave portion 2141 is formed (see FIG. 10 as a reference) re-forms the opening portion 25 of the top sheet 2 (see FIG. 4 for reference).

Next, the principle of forming the opening portion in the resin film sheet 214 when the resin film sheet 214 is passed through the extending tooth roll 230 will be described with reference to FIG. Moreover, the principle does not limit the invention.

The resin film sheet 214 is largely extended by the gear teeth 233 of the upper roller 231 and the gear teeth 235 of the lower roller 232. In the concave portion forming step, the portion where the concave portion 2141 (see FIG. 10 is referred to as a reference) is formed so that the resin film sheet 214 is thinned and the damage is imparted by the lattice-like convex portion 224 of the embossing roll 221, so that the strength is weak, and the resin is weak. The concave portion 2141 of the film sheet 214 is broken to be extended. Therefore, the extended portion 236 of the resin film sheet 214, the resin film sheet 214 The concave portion 2141 is broken, and the broken portion of the resin film sheet 214 is enlarged, and an opening portion is formed in the broken portion of the resin film sheet 214.

The resin film sheet 214 is not extended in the portions 237, 238 where the gear teeth 233 of the upper roller 231 and the gear teeth 235 of the lower roller 232 are not engaged. Therefore, in the resin film sheet 241, the gear teeth 233 of the upper roller 231 and the portions 237, 238 where the gear teeth 235 of the lower roller 232 are not engaged, even if the resin film sheet 214 passes through the extending tooth roller 230, the concave portion formed in the above-described concave portion forming step 2141 does not break and does not become an opening.

In the region where the concave portion 2141 is not formed in the resin film sheet 214, the gear teeth 233 of the upper roller 231 and the gear teeth 235 of the lower roller 232 are engaged with the portion 236, and even if the resin film sheet 214 is largely extended, the resin film sheet 214 is not broken. Therefore, in the resin film sheet 214, the opening portion is not formed in the region 14 and the region of the wing portion 6 which are located outside the both side faces 41 of the absorbent body 4 in the width direction of the main body portion 10.

The absorbent article 1 according to the embodiment of the present invention described above can be modified as follows.

(1) If the contact area between the blood modifying agent layer 24 provided on the top sheet 2 of the main body portion 10 and the top sheet 2 of the wing portion 6 can be reduced, the protrusion formed on the top sheet of the wing portion 6 is not limited to the first 1 mountain fold and 2nd mountain fold. For example, the top sheet of the wing portion 6 may be provided with a mountain fold extending in the width direction (X direction). Further, a mountain fold portion extending in the longitudinal direction (Y direction) or the width direction (X direction) in a wave shape may be provided on the top sheet of the wing portion 6. Furthermore, it can also be on the top of the wing 6 A protrusion having a shape of a cylinder, a square column, a hemisphere, or the like is provided.

(2) As in the absorbent article 1A shown in Fig. 14, the side sheets 18A may be provided on both sides of the top sheet 2A. In this case, the wing portion 6 is provided with a side sheet 18A and a back sheet. In this case, the side sheet 18A is a resin film, and the side sheet 18A does not have an opening in the wing portion 6, and includes a protrusion such as the first mountain fold portion 21 and the second mountain fold portion. Thereby, the blood modifying agent applied to the top sheet 2 of the main body portion 10 can be prevented from penetrating the wing portion 6, and the side sheet 18A constituting the wing portion 6 can be peeled off from the back sheet.

The first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion 23 are provided on the side sheet 18A, and the first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion are not provided in the top sheet 2A. twenty three. Further, a non-woven fabric can be used for the top sheet 2A. In such a case, the blood modifying agent applied to the top sheet 2 of the main body portion 10 can be prevented from penetrating the wing portion 6, and the side sheet 18A constituting the wing portion 6 can be peeled off from the back sheet.

In the case where the top sheet 2A is a non-woven fabric, the nonwoven fabric used for the top sheet 2A may be a natural fiber or a chemical fiber. The natural fiber used for the top sheet 2A may, for example, be pulverized cellulose such as pulp or cotton. The chemical fiber used for the top sheet 2A may, for example, be regenerated cellulose such as rayon or fibrillated rayon, semi-synthetic cellulose such as acetate or triacetate, or thermoplastic hydrophobic chemical fiber, and A hydrophilized thermoplastic thermoplastic fiber or the like. The thermoplastic plastic chemical fiber used for the top sheet 2A may, for example, be a single fiber such as polyethylene (PE), polypropylene (PP) or polyethylene terephthalate (PET), and the polyethylene and polypropylene may be connected. Composite fiber such as fiber and core sheath structure dimension.

Moreover, when the side sheet 18A is provided on both sides of the top sheet 2A, the first mountain fold portion 21, the second mountain fold portion 22, and the valley fold portion 23 may be provided on the top sheet 2A.

(3) If the contact area between the blood modifying agent layer 24 provided on the top sheet 2 of the main body portion 10 and the top sheet 2 of the wing portion 6 can be lowered, the discharge outlet facing region 16 in which the blood modifying agent layer is formed is formed. The protrusion formed on the top sheet 2 is not limited to the first ridge portion. For example, a ridge portion extending in the width direction (X direction) may be provided on the top sheet of the discharge port facing region 16 in which the blood modifying agent layer is formed. Further, a ridge portion extending in the longitudinal direction (Y direction) or the width direction (X direction) in a wave shape may be provided in the top sheet of the discharge port opposing region 16 in which the blood modifying agent layer is formed. Further, a protrusion of a shape such as a column, a square column, or a hemisphere may be provided on the top sheet of the discharge port facing region 16 in which the blood modifying agent layer is formed. In such a case, it is also possible to suppress the blood modifying agent of the blood modifying agent layer from penetrating into the wing portion, and the joining force between the top sheet of the wing portion and the back sheet is weak. Further, the blood modifying agent of the blood modifying agent layer can be prevented from being transferred to the top sheet of the wing portion, and the amount of the blood modifying agent of the blood modifying agent layer formed on the top sheet of the discharge port facing region can be reduced.

(4) The layer formed on the skin side surface of the top sheet at least in contact with the excretion contact area of the user's excretory opening is a coating layer coated with a specific composition, and is not limited to the blood modifying agent layer. . For example, an emulsion coating layer coated with an emulsion for preventing dryness of the skin may be provided in at least the surface of the skin side of the top sheet which is in contact with the excretory opening of the user.

[Examples]

In the present invention, the blood modifying agent has a function of lowering the viscosity and surface tension of the blood, and the body fluid does not remain in the top sheet 2 by the blood modifying agent layer 24, and moves to the absorber 4 to be absorbed by the absorber 4. According to the following examples, it was confirmed that the blood modifying agent has a mechanism for lowering the viscosity and surface tension of blood. This confirmation was carried out using a non-woven fabric in which body fluid easily remained as compared with the resin film.

[example 1] [Evaluation of the rate of rewet and the moving speed of the absorber] [Data of blood modifying agent]

Prepare commercially available sanitary napkins. The sanitary tampon is a top sheet formed by a hot air non-woven fabric treated with a hydrophilic agent (composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g/m ² ), and a hot air non-woven fabric ( The second sheet formed by the composite fiber composed of polyester and polyethylene terephthalate, basis weight: 30 g/m ² ), pulp (basis weight: 150-450 g/m ² , more central portion) ), acrylic high-absorbent polymer (basis weight: 15 g/m ² ) and an absorbent body containing a fabric as a core cladding, a water-repellent-treated side sheet, and a back sheet composed of a polyethylene film form.

The blood modifying agents used in the experiments are listed below.

[(a ₁ ) an ester of a chain hydrocarbon tetraol with at least one fatty acid]

‧UNISTAR H-408BRS, manufactured by Nippon Oil Co., Ltd.

Tetrakilyl tetraethyl 4-hexyl carboxylate, weight average molecular weight: about 640

‧UNISTAR H-2408BRS-22, manufactured by Nippon Oil Co., Ltd.

Mixture of pentaerythritol tetrakis(2-ethyl)hexane acid and neopentyl glycol di-2-ethylhexaneate (58:42, weight ratio), weight average molecular weight: about 520

[(a ₂ ) an ester of a chain hydrocarbon triol with at least one fatty acid]

‧Cetiol SB45DEO, manufactured by Cognis Japan Ltd.

Fatty acid is glycerol and fatty acid triester of oleic acid or stearic acid

‧SOY42, made by Nippon Oil Co., Ltd.

C ₁₄ fatty acids: C ₁₆ fatty acids: C ₁₈ fatty acids: C ₂₀ fatty acids (including both saturated and unsaturated fatty acids) contain approximately 0.2:11:88:0.8 by weight of glycerol and fatty acid triesters , weight average molecular weight: 880

‧Three C2L oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.

C ₈ fatty acid: C ₁₀ fatty acid: C ₁₂ fatty acid contains about 37:7:56 by weight of glycerol and fatty acid triester, weight average molecular weight: about 570

‧Three CL oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.

C ₈ fatty acid: C ₁₂ fatty acid contains about 44:56 by weight of glycerol and fatty acid triester, weight average molecular weight: about 570

‧Panasate 810s, manufactured by Nippon Oil Corporation

C ₈ fatty acid: C ₁₀ fatty acid contains about 85:15 by weight of glycerol and fatty acid triester, weight average molecular weight: about 480

‧Panasate 800, made by Nippon Oil Co., Ltd.

Fatty acid is all octane acid (C ₈ ) glycerol and fatty acid triester, weight average molecular weight: about 470

‧Panasate 800B, made by Nippon Oil Co., Ltd.

The fatty acid is all 2-ethyl hexane acid (C ₈ ) glycerol and fatty acid triester, weight average molecular weight: about 470

‧NA36, made by Nippon Oil Co., Ltd.

C ₁₆ fatty acids: C ₁₈ fatty acids: C ₂₀ fatty acids (including both saturated and unsaturated fatty acids) contain about 5:92:3 by weight of glycerol and fatty acid triesters, weight average molecular weight: about 880

‧Three coconut oil fatty acid glycerides, manufactured by Nippon Oil Co., Ltd.

C ₈ fatty acids: C ₁₀ fatty acids: C ₁₂ fatty acids: C ₁₄ fatty acids: C ₁₆ fatty acids (including both saturated and unsaturated fatty acids) contain a weight ratio of about 4:8:60:25:3 Glycerol and fatty acid triester, weight average molecular weight: 670

‧ Caprylic diglyceride, manufactured by Nippon Oil Co., Ltd.

Fatty acid is a diester of glycerol and fatty acid of octanoic acid, weight average molecular weight: 340

[(a ₃ ) an ester of a chain hydrocarbon diol with at least one fatty acid]

‧Komubolu BL, made by Nippon Oil Co., Ltd.

Butyric acid (C ₁₂ ) monoester of butanediol, weight average molecular weight: about 270

‧Komu Bolu BS, made by Nippon Oil Co., Ltd.

Octadecanoic acid (C ₁₈ ) monoester of butanediol, weight average molecular weight: about 350

‧UNISTAR H-208BRS, manufactured by Nippon Oil Co., Ltd.

Diethyl 2-ethylhexane acid neopentyl glycol, weight average molecular weight: about 360

[(c ₂ ) an ester of a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid, an alkoxy acid or a side acid and at least one aliphatic monohydric alcohol]

‧O-Ethyl tributyl tributyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd.

Weight average molecular weight: about 400

[(c ₃ ) an ester of a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or a side acid and at least one aliphatic monohydric alcohol]

‧Dioctyl adipate, manufactured by Wako Pure Chemical Industries

Weight average molecular weight: about 380

[(d ₃ ) ester of fatty acid with aliphatic monohydric alcohol]

‧Eliteru WE20, manufactured by Nippon Oil Co., Ltd.

Ester of dodecanoic acid (C ₁₂ ) and dodecyl alcohol (C ₁₂ ), weight average molecular weight: about 360

‧Eliteru WE40, made by Nippon Oil Co., Ltd.

Ester of tetradecanoic acid (C ₁₄ ) and dodecyl alcohol (C ₁₂ ), weight average molecular weight: about 390

[(e ₁ ) Polyoxygenated C ₂ ~C ₆ alkanediol]

‧UNIOL D-1000, manufactured by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 1,000

‧UNIOL D-1200, manufactured by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 1,200

‧UNIOL D-3000, manufactured by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 3,000

‧UNIOL D-4000, manufactured by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 4,000

‧UNIOL PB500, manufactured by Nippon Oil Co., Ltd.

Polytetramethylene glycol, weight average molecular weight: about 500

‧UNIOL PB700, manufactured by Nippon Oil Corporation

Polyoxybutylene polyoxypropylene glycol, weight average molecular weight: about 700

‧UNIOL PB1000R, manufactured by Nippon Oil Co., Ltd.

Polytetramethylene glycol, weight average molecular weight: about 1000

[(e ₂ ) an ester of polyoxygenated C ₂ ~C ₆ alkanediol with at least one fatty acid]

‧WILBRIDE cp9, made by Nippon Oil Co., Ltd.

a compound in which an OH group at both ends of polytetramethylene glycol is esterified with palmitic acid (C ₁₆ ), weight average molecular weight: about 1,150

[(e ₃ ) polyoxygenated C ₂ ~C ₆ alkanediol with at least one fatty acid ether]

‧UNILUBE MS-70K, manufactured by Nippon Oil Co., Ltd.

Stearic acid decyl ether of polypropylene glycol, about 15 repeating units, weight average molecular weight: about 1,140

[(e ₅ ) polyoxygenated C ₂ -C ₆ alkanediol and chain hydrocarbon tetraol, chain hydrocarbon triol, or ether of chain hydrocarbon diol]

‧UNILUBE 5TP-300KB

Polyoxyethylene polyoxypropylene pentaerythritol ether formed by pentaerythritol 1 molar addition of ethylene oxide 5 moles and propylene oxide 65 moles, weight average molecular weight: 4,130

‧UNIOL TG-3000, manufactured by Nippon Oil Co., Ltd.

Glyceryl ether of polypropylene glycol, about 16 repeating units, weight average molecular weight: about 3,000

‧UNIOL TG-4000, manufactured by Nippon Oil Co., Ltd.

Glyceryl ether of polypropylene glycol, about 16 repeating units, weight average molecular weight: about 4,000

[(f ₁ )chain alkane]

‧PARLEAM6, made by Nippon Oil Co., Ltd.

a branched chain hydrocarbon formed by copolymerizing a flowing isoparaffin, isobutylene and n-butene, followed by addition of hydrogen, a degree of polymerization: about 5 to about 10, and a weight average molecular weight of about 330

[other materials]

‧NA50, made by Nippon Oil Co., Ltd.

Adding hydrogen to NA36, reducing the double bond ratio of glycerol and fatty acid from the unsaturated fatty acid of the raw material, weight average molecular weight: about 880

‧(octanoic acid/tannic acid) monoglyceride, manufactured by Nippon Oil Co., Ltd.

Octanoic acid (C ₈ ) and decanoic acid (C ₁₀ ) contain a monoester of glycerol and fatty acid in a weight ratio of about 85:15, weight average molecular weight: about 220

‧Monomuls 90-L2 lauric acid monoglyceride, manufactured by Cognis Japan Ltd.

‧Isopropyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd.

Weight average molecular weight: about 230

‧ Malate diisostearyl methacrylate

Weight average molecular weight: about 640

‧UNIOL D-400, manufactured by Nippon Oil Co., Ltd.

Polypropylene glycol, weight average molecular weight: about 400

‧PEG1500, made by Nippon Oil Co., Ltd.

Polyethylene glycol, weight average molecular weight: about 1,500 ~ about 1,600

‧NONION S-6, made by Nippon Oil Co., Ltd.

Polyoxyethylene monostearate, about 7 repeat units, weight average molecular weight: about 880

‧WILBRIDE s753, manufactured by Nippon Oil Co., Ltd.

Polyoxyethylene polyoxypropylene polyoxybutylene glycerin, weight average molecular weight: about 960

‧UNIOL TG-330, manufactured by Nippon Oil Co., Ltd.

Glyceryl ether of polypropylene glycol, repeating unit of about 6, weight average molecular weight: about 330

‧UNIOL TG-1000, manufactured by Nippon Oil Co., Ltd.

Glyceryl ether of polypropylene glycol, about 16 repeating units, weight average molecular weight: about 1,000

‧UNILUBE DGP-700, manufactured by Nippon Oil Co., Ltd.

Diglyceryl ether of polypropylene glycol, repeating unit of about 9, weight average molecular weight: about 700

‧UNIOX HC60, manufactured by Nippon Oil Co., Ltd.

Polyoxyethylene hardened castor oil, weight average molecular weight: about 3,570

‧Vaseline, made by Cognis Japan Ltd.

Hydrocarbon, semi-solid from petroleum

The IOB, melting point and water solubility of the above samples are shown in Table 2 below. Further, the water solubility is measured according to the above method, and desalination at 100 g 20.0 g of water was added, and the sample dissolved after 24 hours was evaluated as "20 g <", and in 100 g of demineralized water, the sample dissolved in 0.05 g but not dissolved in 1.00 g was evaluated to be 0.05 to 1.00 g. Further, regarding the melting point, "<45" has a melting point of less than 45 °C.

The skin contact surface of the top sheet of the above sanitary napkin is coated with the above blood modifying agent. Each blood modifying agent and blood modifying agent are directly used at room temperature, and the blood modifying agent is heated to a melting point of +20 ° C when the room temperature is solid, and then, using a control seam HMA gun, each The blood modifying agent was micronized, and the entire skin contact surface of the top sheet was applied so as to have a basis weight of about 5 g/m ² .

Fig. 15 is an electron micrograph of the skin contact surface of the top sheet in the physiological sanitary napkin (No. 2-5) containing the top C 3L oil fatty acid glyceride. As can be seen from Fig. 15, the tri-C2L oil fatty acid glyceride adhered to the surface of the fiber in the form of fine particles.

The rewet rate and the moving speed of the absorbent body were measured in accordance with the above method. The results are shown in Table 2 below.

[experiment method]

On the top sheet containing each blood modifying agent, an open acrylic plate (200 mm × 100 mm, 125 g, with a hole of 40 mm × 10 mm in the center) was placed, and the horse was EDTA blood (37 ± 1 ° C) from the above hole. In order to prevent coagulation, 3 g of ethylenediaminetetraacetic acid (hereinafter referred to as "EDTA") was added to the blood, and the mixture was dropped using a pipette (first time). After 1 minute, the horse was EDTA at 37±1 °C. Blood 3g from the hole of the acrylic plate to suck The measuring tube was dropped again (the second time).

Immediately after the dropping of the second blood, the acrylic plate was removed, and 10 pieces of filter paper (ADVANTEC Toyo Co., Ltd. qualitative filter paper No. 2, 50 mm × 35 mm) were placed in the place where the blood was dropped, and the pressure was 30 g from the top. Place the weight in /cm ² way. After 1 minute, the filter paper was taken out, and the "reverse bleed rate" was calculated by the following formula.

Infiltration rate (%) = 100 × (quality of filter paper after test - original filter paper quality) / 6

Further, in addition to the evaluation of the rewet rate, the time during which the blood is moved from the top sheet to the absorber after the second blood drop is measured is the "absorbent moving speed". The moving speed of the absorbent body refers to the time from when the absorbent body is put into the blood until the red color of the blood is not visible on the surface of the top sheet and inside.

The results of the rewet ratio and the moving speed of the absorbent body are shown in Table 2 below.

Next, the whiteness of the skin contact surface of the top sheet after the test of the moving speed of the absorbent body was visually evaluated based on the following criteria.

◎: The red color of the blood hardly remains, and it is impossible to distinguish between the place where the blood exists and the place where it does not exist.

○: Although there are some residues in the red color of the blood, it is difficult to distinguish between the place where the blood exists and the place where it does not exist.

△: There are some residues in the red color of the blood, and the place where the blood exists is known.

×: The red color of the blood directly remains

The results are shown in Table 2 below.

When there is no blood modifying agent, the re-infiltration rate is 22.7%, and the moving speed of the absorbent body is more than 60 seconds, but the osmotic rate of the glycerol and the fatty acid triester is less than 7.0%, and the moving speed of the absorbent body is at After 8 seconds or less, it is known that the absorption performance is greatly improved. However, in the triester of glycerin and fatty acid, at the NA50 having a melting point exceeding 45 ° C, no significant improvement in the absorption performance was observed.

Similarly, it is understood that the absorption performance is greatly improved in a blood modifying agent having a water solubility of from about 0.00 to about 0.60 IOB, a melting point of about 45 ° C or less, and a water solubility of about 0.00 to about 0.05 g to 100 g of water at 25 ° C.

Next, the sanitary napkins of No. 2-1 to 2-47 are used by a plurality of voluntary subjects, and even in the sanitary napkin containing the blood modifying agent of No. 2-1 to 2-32, After absorbing the menstrual blood, the top sheet is not sticky, and the top sheet is refreshing.

In addition, in the sanitary napkins of No. 2-1 to No. 2-32, the sanitary napkins containing the blood modifying agents No. 2-1 to 11, 15 to 19 and 32 are absorbed. The skin contact surface of the top sheet after menstrual blood is not stained with blood, and the answer is less unpleasant.

[Example 2]

Regarding the various blood of animals, the rate of rewet was evaluated in accordance with the above method. The blood that can be used in the experiment is as follows.

[Animal species]

(1 person

(2) Horse

(3) sheep

[blood species]

‧Defibration: After taking blood, stir it in a conical flask with glass beads for about 5 minutes.

‧EDTA blood: Add 12% EDTA‧2K physiological saline solution 0.5mL to venous blood 65mL

[Division]

Serum or plasma: each defibrinated blood or EDTA blood was centrifuged at room temperature for about 10 minutes at room temperature for 10 minutes.

Blood cells: The serum is removed from the blood, and the residue is washed twice with phosphate buffered physiological saline (PBS), followed by phosphate buffered physiological saline solution containing serum.

An absorbent article was produced in the same manner as in Example 2 except that the trisodium C2L oil fatty acid glyceride was applied so that the basis weight was about 5 g/m ² , and the rewet ratio was evaluated for each of the above blood. Each blood was measured three times, and the average value was used.

The results are shown in Table 3 below.

The same tendency as the horse EDTA blood obtained in Example 2 was also obtained in the blood of humans and sheep. Also, the same tendency was observed in defibrinated blood and EDTA blood.

[Example 3] [Evaluation of blood retention]

The blood retention in the top sheet containing the blood modifying agent and the top sheet containing no blood modifying agent was evaluated.

[experiment method]

(1) The skin contact surface of the top sheet formed by hot air non-woven fabric (composite fiber composed of polyester and polyethylene terephthalate, basis weight: 35 g/m ² ), using three C2L oil fatty acid glycerides The control joint HMA gun was micronized and applied in such a manner that the basis weight became about 5 g/m ² . Further, for comparison, those who do not apply the tri-C2L oil fatty acid glyceride are also prepared. Next, both the top sheet coated with the tri-C2L oil fatty acid glyceride and the uncoated top sheet were cut to a size of 0.2 g, and the mass (a) of the sterile cell filtration cap tube + top sheet was correctly determined.

(2) About 2 mL of horse EDTA blood was added from the skin contact surface side, and allowed to stand for 1 minute.

(3) The sterile cell filtration cap tube was placed in a centrifuge tube, and subjected to low-speed centrifugation to remove excess horse EDTA blood.

(4) Determine the weight (b) of the top sheet containing the sterile cell filter cap + horse EDTA blood.

(5) The initial absorption amount (g) per 1 g of the top sheet was calculated according to the following formula.

Initial absorption = [weight (b) - weight (a)] / 0.2

(6) The sterile cell filtration cap tube was further placed in a centrifuge tube, and centrifuged at about 1200 G for 1 minute at room temperature.

(7) The weight (c) of the top sheet containing the sterile cell filter cap + horse EDTA blood was measured.

(8) The amount of absorption (g) per 1 g of the top sheet after the test was calculated according to the following formula.

Absorption after test = [weight (c) - weight (a)] / 0.2

(9) The blood retention rate (%) was calculated according to the following formula.

Blood retention rate (%) = 100 × absorption after test / initial absorption

Further, the measurement was carried out three times, and the average value thereof was used. The results are shown in Table 4 below.

It is suggested that the top sheet containing the blood modifying agent has low blood retention and can quickly move to the absorber after absorbing blood.

[Example 4] [Voice of blood containing blood modifying agent]

The viscosity of blood containing a blood modifying agent was measured using a Rheometric Expansion System ARES (Rheometric Scientific, Inc). To the horsetail fiber, 2% by mass of Panasate 810s was added, and the sample was gently stirred to form a sample, and the sample was placed in a parallel plate having a diameter of 50 mm, and the gap was 100 μm, and the viscosity was measured at 37 ± 0.5 °C. Because of the parallel plate, although the uniform shear rate was not applied to the sample, the average shear rate indicated by the machine was 10 s ^-1 .

The viscosity of the horse-defibrinated blood containing 2% by mass of Panasate 810s was 5.9 mPa·s, and on the other hand, the viscosity of the horse-depleted blood containing no blood modifying agent was 50.4 mPa·s. Therefore, it can be seen that the horse defibrinated blood containing 2% by mass of Panasate 810s is compared with the case where no blood modifying agent is contained. Compared, it drops about 90% viscosity. The blood is known to contain components such as blood cells and has a property of shaking, but it is considered that the blood modifying agent of the present invention lowers the viscosity of blood in a low viscosity domain. It is believed that by reducing the viscosity of the blood, the absorbed menstrual blood can be quickly moved from the top sheet to the absorber.

[Example 5] [Microscopic photo of blood containing blood modifying agent]

The menstrual blood of the healthy volunteers was collected on Saran Wrap (trademark), and Panastate 810s dispersed in 10 times by mass of phosphate buffered physiological saline was added to a part thereof to make the concentration of Panasee 810s 1% by mass. The menstrual blood was dropped on a glass slide, covered with a cover glass, and the red blood cell state was observed with an optical microscope. A photomicrograph of menstrual blood without a blood modifying agent is shown in Fig. 16(a), and a photomicrograph of a menstrual blood containing Panasate 810s is shown in Fig. 16(b).

Fig. 16 shows that in the menstrual blood containing no blood modifying agent, the red blood cells form a collecting block such as a chain, but in the menstrual blood containing Panasate 810s, the red blood cells are stably dispersed. Therefore, it is suggested that the blood modifying agent plays a role in the blood to stabilize the red blood cells.

[Example 6] [Surface tension of blood containing blood modifying agent]

The surface tension of the blood containing the blood modifying agent was measured by a drip drop method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science Co., Ltd. Surface tension is added to the sheep defibration blood by adding a specific amount of blood modifier, fully vibrating The measurement was carried out after the action. The measurement was automatically performed by a machine, and the density γ was obtained by the following equation (see Fig. 17 for reference).

γ=g×ρ×(de) ² ×1/H

g: gravity constant

1/H: correction term determined by ds/de

ρ: density

De: maximum diameter

Ds: the diameter of the position where only the de is raised by the drop end

The density ρ is measured by the vibration density test method according to JIS K 2249-1995, "Density Test Method and Density ‧ Mass ‧ Capacity Conversion Table", using the temperature shown in Table 5 below. For the measurement, the DA-505 of Kyoto Electronics Industry Co., Ltd. was used. The results are shown in Table 5.

As can be seen from Table 5, the blood modifying agent has a water solubility of about 0.00 to about 0.05 g for 100 g of water at 25 ° C, although it is also known to dissolve in water. Very low in sex but can reduce the surface tension of blood. It is considered that by lowering the surface tension of blood, the absorbed blood does not remain between the fibers of the top sheet, and can be quickly moved to the absorber.

One or a plurality of embodiments and modifications may be combined. Modifications can also be combined with each other.

The above description is only an example, and the invention is not limited to the above embodiment.

Claims (9)

An absorbent article comprising a top sheet having a liquid permeability provided on a skin side, a liquid impervious back sheet provided on a garment side, and the top sheet and the back sheet The main body of the liquid-retaining absorbent body provided between the absorbent body and the pair of wing portions including the top sheet and the back sheet extending from the both side edges of the main body portion are characterized by The top sheet of the main body portion has a composition coating layer coated with a specific composition on at least the surface of the skin side contacting the excretory opening of the user, and the top sheet is a resin film, and the top sheet is The at least the excretory opening contact region has an opening, the wing portion does not have an opening, and the top sheet includes a protrusion in the wing portion, and the top sheet includes the first portion extending in the longitudinal direction and alternately arranged in the width direction. a mountain fold portion and a valley fold portion, and a second mountain fold portion extending in a direction intersecting the first mountain fold portion, wherein the protrusion portion is the first mountain fold portion and the second portion Fold. An absorbent article comprising a top sheet having a liquid permeability provided on a skin side, a liquid impervious back sheet provided on the garment side, the top sheet and the back sheet a liquid-retaining absorber provided between the liquid retaining body and a pair of side sheets disposed on both sides of the top sheet, and a side sheet extending from a side edge of the body portion in a width direction a pair of wings of the back sheet A retractable article characterized in that the excrement port contact region of the top sheet on the skin side contacting at least the user's excretory opening has a composition coating layer coated with a specific composition, and the side sheet is a resin film The side sheet does not have an opening in the wing portion, but includes a protrusion. The side sheet includes a first mountain portion and a valley portion that extend in the longitudinal direction and are alternately arranged in the width direction. A second mountain fold portion extending in a direction in which the mountain fold portion intersects, and the protrusion portion is the first mountain fold portion and the second mountain fold portion. The absorbent article according to claim 1 or 2, wherein the composition coating layer is formed such that the pair of wing portions are folded inward in the width direction so that the edges of the pair of wing portions in the width direction are in contact with each other At the time, the pair of wings are disposed within the shielded range. The absorbent article according to claim 1 or 2, wherein the sealing portion is formed at an edge portion on the outer side in the width direction of the pair of wing portions. The absorbent article according to claim 1 or 2, wherein the composition is a blood modifying agent having an IOB of 0.00 to 0.60, a melting point of 45 ° C or less, and a water solubility of 0.00 to 0.05 g per 100 g of water at 25 ° C. The absorbent article according to claim 5, wherein the blood modifying agent is composed of (i) to (iii), (i) hydrocarbon, (ii) having (ii-1) hydrocarbon portion, and (ii- 2) The carbonyl group (-CO-) and the oxy group (-O-) interposed between the CC single bonds of the hydrocarbon moiety a compound selected from the group consisting of one or plural identical or different groups, and (iii) a carbonyl group (-CO) having a (iii-1) hydrocarbon moiety and a CC single bond of (iii-2) the aforementioned hydrocarbon moiety -) or a plurality of identical or different groups selected from the group consisting of oxy (-O-), and (iii-3) a carboxyl group (-COOH) and a hydroxyl group which replace the hydrogen atom of the hydrocarbon moiety ( -OH) selected from the group consisting of one or a plurality of compounds of the same or different groups selected by the group, and any combination thereof, wherein, in the compound of (ii) or (iii), When two or more oxy groups are inserted, each oxy group is not adjacent. The absorbent article according to claim 5, wherein the blood modifying agent is composed of (i') to (iii'), (i') hydrocarbon, and (ii') having (ii'-1) hydrocarbon portion And (ii'-2) a carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO-), and an ether bond interposed between CC single bonds of the aforementioned hydrocarbon moiety One or a plurality of identical or different bonded compounds selected by the group consisting of (-O-), and (iii') having (iii'-1) hydrocarbon moiety and (iii'-2) hydrocarbon A group consisting of a carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO-), and an ether bond (-O-) inserted between a part of the CC single bond. One or plural selected from the group consisting of one or plural identical or different bonds, and (iii'-3) a group consisting of a carboxyl group (-COOH) and a hydroxyl group (-OH) which replace the hydrogen atom of the hydrocarbon moiety. The same or different base compounds, And a group consisting of any combination thereof, wherein, in the compound of (ii') or (iii'), when two or more identical or different bonds are inserted, the bonds are not adjacent. . The absorbent article according to claim 5, wherein the blood modifying agent has a chain hydrocarbon moiety and a hydrogen atom replacing the chain hydrocarbon moiety in the following (A) to (F) and (A) (A1). a compound having 2 to 4 hydroxyl groups and (A2) an ester having a chain hydrocarbon moiety and a compound which substitutes one carboxyl group of a hydrogen atom of the chain hydrocarbon moiety, and (B) (B1) having a chain hydrocarbon moiety and substituting the aforementioned a compound having 2 to 4 hydroxyl groups of a hydrogen atom of a chain hydrocarbon moiety and (B2) an ether having a chain hydrocarbon moiety and a hydroxyl group substituted for a hydrogen atom of the chain hydrocarbon moiety, and (C) (C1) a chain hydrocarbon portion and a carboxylic acid, a hydroxy acid, an alkoxy acid or a pendant oxyacid which replaces 2 to 4 carboxyl groups of a hydrogen atom of the aforementioned chain hydrocarbon moiety, and (C2) have a chain hydrocarbon moiety and a substituted chain hydrocarbon An ester of a compound having a hydroxyl group of a part of a hydrogen atom, (D) an ether bond (-O-), a carbonyl bond (-CO-) interposed between a chain hydrocarbon moiety and a CC single bond of the aforementioned chain hydrocarbon moiety. a compound selected from the group consisting of an ester bond (-COO-) and a carbonate bond (-OCOO-), (E) a polyoxy C ₂ -C ₆ alkanediol, or Alkyl ester or alkyl ether And (F) a chain hydrocarbon, and the group consisting of any combination of their being selected. The absorbent article according to claim 5, wherein the blood modifying agent is an ester of (a ₁ ) chain hydrocarbon tetraol and at least one fatty acid, (a ₂ ) chain hydrocarbon triol and at least one fatty acid Ester, (a ₃ ) chain hydrocarbon diol and at least one fatty acid ester, (b ₁ ) chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol ether, (b ₂ ) chain hydrocarbon triol And an ether of at least one aliphatic monohydric alcohol, (b ₃ ) a chain hydrocarbon diol and at least one aliphatic monohydric alcohol, (c ₁ ) a chain hydrocarbon tetracarboxylic acid having four carboxyl groups, a hydroxyl group An acid, alkoxy acid or an acid ester of a side acid with at least one aliphatic monohydric alcohol, (c ₂ ) a chain hydrocarbon tricarboxylic acid having three carboxyl groups, a hydroxy acid, an alkoxy acid or a side acid An ester of at least one aliphatic monohydric alcohol, (c ₃ ) a chain hydrocarbon dicarboxylic acid having two carboxyl groups, a hydroxy acid, an alkoxy acid or an ester of a side acid and at least one aliphatic monohydric alcohol; (d ₁ ) an aliphatic monohydric alcohol and an aliphatic monohydric alcohol ether, (d ₂ ) dialkyl ketone, (d ₃ ) fatty acid and an aliphatic monohydric alcohol ester, (d ₄ ) dialkyl carbonate , (e ₁₎ polyoxy C ₂ ~ C ₆ alkylene glycol, (e ₂₎ polyoxy C ₂ ~ C ₆ alkylene glycol and at least one fatty acid Ether ester, (e ₃₎ polyoxy C ₂ ~ C ₆ alkylene glycol and at least one of an aliphatic monohydric alcohol, (e ₄₎ polyoxy C ₂ ~ C ₆ alkylene glycol and a chain hydrocarbon tetracarboxylic acid, Chain hydrocarbon tricarboxylic acid, or ester of chain hydrocarbon dicarboxylic acid, (e ₅ ) polyoxy C ₂ ~ C ₆ alkanediol and chain hydrocarbon tetraol, chain hydrocarbon triol, or chain hydrocarbon glycol The group consisting of ether, and (f ₁ ) chain alkane, and any combination thereof is selected.